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Abstract
Background: The neural crest is a transient embryonic stem cell population.
Hypoxia inducible factor (HIF)-2α is associated with neural crest stem cell
appearance and aggressiveness in tumors. However, little is known about its
role in normal neural crest development.
Results: Here, we show that HIF-2α is expressed in trunk neural crest cells of
human, murine, and avian embryos. Knockdown as well as overexpression of
HIF-2α in vivo causes developmental delays, induces proliferation, and self-
renewal capacity of neural crest cells while decreasing the proportion of neural
crest cells that migrate ventrally to sympathoadrenal sites. Reflecting the
in vivo phenotype, transcriptome changes after loss of HIF-2α reveal enrich-
ment of genes associated with cancer, invasion, epithelial-to-mesenchymal
transition, and growth arrest.
Conclusions: Taken together, these results suggest that expression levels of
HIF-2α must be strictly controlled during normal trunk neural crest develop-
ment and that dysregulated levels affects several important features connected
to stemness, migration, and development.
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1 | INTRODUCTION
The neural crest is a multipotent stem cell population that
is unique to vertebrate embryos. Originating from the ecto-
dermal germ layer, premigratory neural crest cells arise in
the dorsal neural tube during neurulation and are charac-
terized by expression of transcription factors like FOXD3,
TFAP2, and SOXE.1 Neural crest cells subsequently
undergo an epithelial-to-mesenchymal transition (EMT) to
delaminate from the neuroepithelium, then migrate exten-
sively throughout the embryo, populating distant sites.
Upon reaching their final destinations, neural crest cells
form a large variety of cell types, as diverse as elements of
the craniofacial skeleton, melanocytes of the skin, adrenal
chromaffin cells, and sympathetic neurons and glia.2-5
Under normal conditions, hypoxia inducible factor
(HIF)-2α is stabilized at low oxygen levels and responds
to hypoxia by initiating a transcriptional program for cel-
lular adaptation to changes in energy demand. Tumor
cells that express high levels of HIF-2α together with
numerous neural crest markers have been detected in
perivascular niches despite the access to oxygen in these
areas.6-8 Accordingly, HIF-2α can become abnormally
stabilized at physiological oxygen tensions (5% O2)
in vitro.6,9
Previous studies in chick, quail and Xenopus embryos
have shown that related HIF1A (encoding HIF-1α) and
ARNT (encoding HIF-1β, transcriptional binding partner
of both HIF-α isoforms) genes co-localize and are ubiqui-
tously expressed within the developing embryo, as investi-
gated at time points up to HH14 (HH stages in chick
embryos).10-14 EPAS1 (encoding HIF-2α) is however
expressed in a more distinct pattern and in tissues not
expressing HIF1A (extraembryonic and endothelial
cells).12 Embryos experience a milieu with low oxygena-
tion (5% O2), particularly before the blood circulation is
fully functional, which starts at stage HH14.11 Despite
this, HIF-2α is not ubiquitously expressed. In addition,
trunk neural crest cells form mainly after commencement
of vasculogenesis and hence are not affected by high
(20%-40%) oxygen.11 This is in concordance with data
from Barriga et al, suggesting that HIF-α stability in neu-
ral crest cells can be controlled by both oxygen-dependent
as well as oxygen-independent mechanisms14 as suggested
in other systems, including neuroblastoma.9
Here, we explore the role of HIF-2α during normal
development up to the time point when trunk neural
crest cells have completed emigration and begin to
populate sympathetic ganglia. We show that HIF-2α is
expressed in migrating trunk neural crest and sympa-
thetic neuroblasts in human, murine, and avian embryos.
RNA sequencing of trunk neural crest cells with dys-
regulated HIF-2α levels demonstrates a shift in the global
transcriptional program, resulting in enrichment of genes
associated with tumor morphology, invasion, EMT, and
arrested embryo growth. Knockdown and overexpression
experiments in chick embryos in vivo result in a delay in
embryonic growth, altered expression of trunk neural
crest genes, increased proliferation and disrupted trunk
neural crest cell migration. Consistent with this, in vitro
HIF-2α knockout crestospheres display increased self-
renewal capacity. The results suggest that expression
levels of HIF-2α must be strictly controlled for proper
neural crest development. These findings enhance our
understanding of how genes dysregulated in normal
development and tumor cells connect, and how oxygen
sensing HIF-2α plays noncanonical roles during trunk
neural crest development.
2 | RESULTS
2.1 | HIF-2α is expressed in migratory
trunk neural crest cells in chick embryos
The presence of neuroblastoma cells expressing HIF-2α
in perivascular tumor niches indicates poor prognosis.
That these cells express stem cell- and neural crest associ-
ated proteins raises the intriguing possibility that they
may constitute a tumor-initiating subpopulation resem-
bling embryonic neural crest cells. As a first step in
exploring the role of HIF-2α in the embryo, we examined
its spatiotemporal expression during normal trunk neural
crest development. To this end, we performed immuno-
cytochemistry in transverse sections through the trunk
axial level of stage HH11, HH13, and HH18 embryos. We
detected low levels of HIF-2α protein in neural crest cells
within the neural tube of HH11 and HH13 embryos
(Figure 1A,B, respectively), as well as other sites in the
embryo. This contrasts with previous reports on HIF-2α
reporting expression exclusively in extraembryonic tissue
at these stages.13 Indeed, we also detect HIF-2α staining
in extraembryonic tissue of HH11 and HH13 embryos
(Figure 1A,B). Differences in results may be due to differ-
ent detection methods (eg, in situ hybridization in previ-
ous reports vs antibody staining here), staging, or species
differences. At these stages, trunk neural crest cells are
still premigratory, and although not all cells within
the neural tube will emigrate, a large fraction of these
cells will generate progeny that become bona fide neural
crest cells. We further detected HIF-2α in cells that
had delaminated from the neural tube and initiated
migration in older embryos (HH18; Figure 1C), in line
with data from Nanka et al.12 To identify these cells as
trunk neural crest cells, we co-stained with HNK-1 anti-
body (Figure 1D). Secondary antibody alone confirmed
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that there was no nonspecific binding (Figure 1E), and
we ruled out that the primary antibody (ab199, rabbit
anti-HIF-2α; Abcam) also detected related protein HIF-
1α by knocking down both HIF-α isoforms and blotting
for HIF-2α. The antibody did not detect any protein in
the HIF-2α siRNA lane, ensuring specificity (Figure 1F).
Along the same line, we used immunohistochemistry to
stain cells cultured at normoxia (21%) or hypoxia (1% O2)
with the NB100-132 primary antibody (mouse anti-HIF-
2α; Novus Biologicals) and as expected only observed
FIGURE 1 Hypoxia inducible factor (HIF)-2α is
expressed in trunk neural crest cells. A,C,
Immunostaining of HIF-2α in sections from trunk
axial level of wild-type chick embryos at HH11, A,
HH13, B, and HH18, C. Arrow denotes ventrally
migrating HIF-2α positive cells. D, Co-
immunostaining of HIF-2α and HNK1 (marker of
migrating neural crest) in sections from trunk axial
level of wild-type HH18 chick embryos. Arrows
denote migrating cells double positive for the two
proteins. E, Sections of HH13 wild-type embryo
immunostained with DAPI for visualization of nuclei
and secondary antibody only (donkey anti-rabbit
Alexa Fluor-546). F, Western blot analysis for
detection of HIF-2α protein at 21% and 1% O2
following siRNA mediated knockdown of HIF-1α or
HIF-2α. DIP treated cells were used as a positive
control and SDHA as loading control. Lanes between
21% and 1% siCTRL were removed from this figure,
indicated by the black line. G, Immunohistochemical
staining for HIF-2α in sections of SK-N-BE(2)c
neuroblastoma cells cultured at 21% or 1% O2. H,
Schematic of where oxygen measurements were
performed. I, Oxygen saturation in the trunk of chick
embryos during development measured ex ovo using
microsensor technique. Error bars represent SEM,
n ≥ 3 biologically independent replicates for each
time point
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HIF-2α expression at lowered oxygen concentrations
(Figure 1G). Together with previous data on these
antibodies,6,9,15,16 these results ensure antibody specificity.
2.2 | Development from environmental
to physiological oxygen
In adult vertebrate animals, HIF-2α is canonically induced
at low oxygen levels. To understand variations in oxygen
consumption during the developmental stages of interest,
we measured O2 saturation in real time in the developing
chick embryo utilizing STOX microsensors. Oxygen avail-
ability is referred to as changes of full saturation, meaning
that anything below 100% saturation reflects a reduction
from what liquid would hold if in equilibrium with air,
which is to be expected when organisms develop into 3D
structures. Embryos were removed from the egg at desired
developmental time points (minimum three embryos per
time point) and oxygen saturation was measured specifically
within the neural tube at the trunk axial level (Figure 1H).
The handling of embryos outside the egg did not change
intratissue oxygen saturation over the first 4 hours. Since
our measurements were performed within 30 minutes, we
believe that these numbers reflect near-endogenous levels.
Within the trunk neural tube, oxygen saturation starts out
high (up to 85% ± 5 SEM O2 saturation) at trunk specific
premigratory to migratory stages of neural crest develop-
ment (HH10-HH16) and gradually decreases (Figure 1I). At
the time when the majority of trunk neural crest cells have
delaminated from the tube (HH18), oxygen saturation is
low (23% ± 10 SEM O2 saturation), only to rise and fall
again at later time points (Figure 1I).
2.3 | HIF-2α is expressed in sympathetic
neuroblasts in human and mouse embryos
EPAS1 knockout mice have severe abnormalities in the
sympathetic nervous system (SNS)17; consistent with this,
there is some, albeit limited, data suggesting that HIF-2α
is expressed in sympathetic chain ganglia up to murine
day E11.5 (corresponding to human embryonic week 5).
Moreover, mice lacking PHD3 (HIF prolyl hydroxylase),
a gene critical for regulation of HIF-2α, display reduced
SNS function that is rescued by crossing these mutants
with EPAS1+/− mice.18
We have previously shown that HIF-2α is expressed
in sympathetic ganglia of human embryos at embryonic
week 6.5 (E12.5 in mice) but that expression is lost
in these cells at later stages (fetal week 8).19 Here, we
detected expression of HIF-2α positive cells in the dorsal
neural tube, as well as in migrating cells in sections
through the trunk region of a human embryo of embry-
onic week ew5 (Carnegie stage 13; Figure 2A). In con-
trast, there were virtually no HIF-2α positive cells left
within the neural tube at embryonic week ew6 (Carnegie
stage 16; Figure 2B). Rather, positive cells could be
detected migrating along the ventral pathway followed by
sympathoadrenal precursors (Figure 2B). To confirm that
that these HIF-2α positive cells were trunk neural crest
cells in human embryos, we co-stained with HNK-1 anti-
body, which is expressed on migrating neural crest cells
of human embryos similar to expression in the chick
(Figure 2C, cf Figure 1D). This resembled the staining
pattern found in chick embryos, but also highlights some
differences in the number of positive cells as well as tis-
sues positive for HIF-2α (compare Figures 1 and 2). These
differences likely reflect variation between species as well
as the fact that it is difficult to assess exact corresponding
developmental stages between them. We further detected
HIF-2α in sympathetic ganglia in mouse embryos at
E12.5 by staining adjacent sections for HIF-2α and TH
antibodies, with the latter indicating the location of sym-
pathetic ganglia (Figure 2D). HIF-2α is a transcription
factor that localizes to the nucleus but it has lately also
been shown to be expressed in the cytoplasm,6,9,19 though
its role in the cytoplasm remains unknown. Consistent
with this dual localization, we noted HIF-2α expression
in both the nucleus and cytoplasm (Figure 2E), similar to
what has been observed in perivascular oxygenated neu-
roblastoma and glioblastoma cells.6,20
2.4 | Knockdown of HIF-2α delays
embryogenesis and alters gene expression
To examine the role of HIF-2α in vivo, we performed
loss-of-function experiments in chick embryos using a
morpholino-mediated knockdown approach. Functioning
as a surrogate marker, successful electroporation was
confirmed by EGFP expression (Figure 3A). Experimen-
tally, to ensure that we specifically affected the neural
crest and not surrounding tissue such as mesoderm, we
injected from the posterior end of the embryo and elec-
troporated the constructs into the lumen of the neural
tube. We then let the embryos develop for an additional
24 or 44 to 48 hours (for gene expression and staging/
migration assessment, respectively) and analyzed several
potentially affected biological processes. Surprisingly, we
noticed that HIF-2α knockdown embryos were develop-
mentally delayed compared with their control counter-
parts (Figure 3B,C). The stages of embryos following
loss of HIF-2α were determined by their Hamburger
and Hamilton developmental stage in ovo (Figure 3B)
and by counting somites ex ovo (Figure 3C) 44 hours
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postinjection. The number of somites was equal on both
sides and effects observed were embryo wide.
Knockdown of HIF-2α further led to decreased
expression levels of genes representative of early and
migrating neural crest as well as trunk neural crest cells
in particular21,22 (Figure 3D). The cranial neural crest
associated gene HOXA2 was also slightly downregulated
(Figure 3E), though not consistently.
FIGURE 2 Hypoxia inducible factor
(HIF)-2α is expressed in human and
mouse trunk neural crest cells. A,B,
Immunostaining of HIF-2α in sections
from trunk axial level of human embryos
at embryonic week 5, A, and embryonic
week 6, B. Asterisks denote magnified
area in the two right panels. ew,
embryonic week. DAPI was used to
counterstain nuclei. C, Co-
immunostaining of HIF-2α and HNK1
(marker of migrating neural crest) in
sections from trunk axial level of human
embryos at embryonic week 6. Arrows
denote areas staining positive for both
proteins. Right panel: open arrowheads
denote double positive individual cells;
closed arrowheads denote cells positive for
HNK1 alone. D, Immunohistochemical
staining of HIF-2α and TH in adjacent
sections from a mouse embryo at
embryonic day E12.5. TH is used to locate
sympathetic ganglia. Asterisks in left
panels indicate magnified area in middle
panels and dashed square indicates
magnification area in right panels. E,
Magnification of an embryo
immunostained for HIF-2α in a
section from trunk axial level of a human
embryo at embryonic week 6. Closed
arrowheads denote nuclear HIF-2α
staining; open arrowheads denote
cytoplasmic HIF-2α staining
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2.5 | CRISPR/Cas9 mediated knockout
of HIF-2α recapitulates the morpholino
phenotype
Our EPAS1 morpholino is a splice targeting morpholino,
predicted to confer either nonsense-mediated decay of
mRNA or a mutant dysfunctional protein. We could not
convincingly detect any changes in HIF-2α protein expres-
sion following morpholino treatment, nor a shift in protein
size. This could be explained by other mechanisms-of-action
for decrease in protein activity or the mosaicism that arises
with morpholino treatments in chick embryos. To ensure
that the observed biological phenotypes were not due to off-
target effects of our morpholino, we used CRISPR/Cas9 as a
second approach to knock out HIF-2α by designing three
different gRNAs targeting EPAS1 at three different sites.
Functional CRISPR mediated knockout of the HIF-2α pro-
tein was demonstrated by immunofluorescence (Figure 4A).
The fact that both morpholino and several CRISPR/Cas9
constructs with in total four different target sites within the
gene produced the same biological phenotype nicely vali-
dates our results and serves as important controls.
After ensuring electroporation efficiency by EGFP
expression (Figure 4B), we determined the age of the
embryos following CRISPR/Cas9 mediated knockout of the
protein using head- and tail morphology (converted into
HH stage; Figure 4C) or by counting somites (Figure 4D)
36 hours postinjection.
FIGURE 3 Morpholino mediated knockdown of hypoxia inducible factor (HIF)-2α delays embryogenesis. A, Relative mRNA
expression as measured by qRT-PCR. WT, wild-type HH18 embryos. Error bars represent SEM, n = 2 biologically independent replicates.
B,C, Determination of developmental age 44 hours postelectroporation with 50-mispair or EPAS1 targeting morpholinos as assessed by head-
and tail morphology, B, (converted to Hamburger Hamilton (HH) stages. Number of embryos analyzed were n = 20 [50-mispair], n = 16
[EPAS1]) or counting somites ex ovo, C, (number of embryos analyzed were n = 17 (50-mispair), n = 15 [EPAS1]). Statistical significance was
determined by one-way analysis of variance (ANOVA). D,E, Relative mRNA expression of trunk, D, and cranial, E, neural crest associated
genes in dissected neural tube tissue derived from the trunk axial level of embryos electroporated with 50-mispair or EPAS1 morpholinos,
measured by qRT-PCR 24 hours postelectroporation. Data presented as mean of n = 2 biologically independent repeats, error bars denote
SEM. Statistical significance was determined by two-sided student's t test
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FIGURE 4 Legend on next page.
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2.6 | Knockdown of HIF-2α affects cell
numbers along the ventral neural crest
migratory pathway
One of the most important features of neural crest cells
is their migratory ability. Trunk neural crest cells des-
tined to form the sympathetic chain ganglia migrate ven-
trally. Following HIF-2α loss of function using either
morpholino or CRISPR/Cas9, HNK1 positive migratory
trunk neural crest cells were detected on the control side
in all embryos (right panel, left side; Figure 5A-E) as well
as on the side electroporated with nontargeting gRNA
CTRL and control 50-mismatch morpholino (right panel,
left side; Figure 5A,D, respectively). In contrast, loss
of HIF-2α profoundly reduced the number of HNK1 posi-
tive cells migrating to ventral regions of the embryo
(CRISPR/Cas9, Figure 5B,C; morpholino, Figure 5E,F).
2.7 | Overexpression of HIF-2α presents
similar effects as loss-of-function
Similar to the loss-of-function experiments, over-
expression of HIF-2α led to delayed embryonic develop-
ment (Figure 6A) and perturbed migration as visualized
by HNK1 staining (Figure 6B,C). To investigate spatially
whether affected genes (Figures 3D and 4E,F) were
indeed downregulated in neural crest cells (as indicated
by qPCR analyses of gene expression in dissected neural
tubes of electroporated embryos), we performed in situ
hybridization for TFAP2B on whole HIF-2α wild-type
and overexpression embryos. We could detect down-
regulated levels of TFAP2B in delaminated cells on the
electroporated side of embryos after overexpression of
HIF-2α, visualized by whole embryo imaging (Figure 6D)
and transverse sections (Figure 6E) at trunk axial level.
We also performed qPCR to extend our panel of investi-
gated genes and observed slightly suppressed expression
of neural crest- and trunk specific genes (Figure 7A,B)
whereas expression of cranial neural crest gene HOXA2
was instead slightly induced (Figure 7C). The less profound
effects on neural crest genes from overexpression as com-
pared to knockdown may be attributed HIF-2α expression
level dependent efficiency of the constructs. Overexpression
of EPAS1 was confirmed by qRT-PCR (Figure 7D).
2.8 | HIF-2α knockout does not affect
SOX9 distribution
SOX9, a member of the SoxE family of transcription fac-
tors, is important for neural crest fate. It is expressed in
premigratory neural crest cells at all axial levels and pro-
motes their lineage progression. Importantly, transverse
sections through the trunk of embryos electroporated
with control (Figure 8A) or two different EPAS1 targeting
gRNA constructs (EPAS1.1 and EPAS1.3, Figure 8B,C,
respectively) showed no differences in SOX9 expression.
These results suggest that neural crest lineage specifica-
tion, at least as assessed by SOX9, was unaffected by loss
of HIF-2α.
2.9 | Trunk neural crest cells proliferate
extensively in response to dysregulated
HIF-2α
We next examined cell proliferation in premigratory and
early migrating trunk neural crest cells after loss of HIF-2α
using real-time EdU pulse chase labeling optimized for
avian embryos.23 Quantifying the proportion of electro-
porated premigratory and early migrating trunk neural crest
cells that had incorporated EdU (by counting RFP+ only
and RFP+/GFP+ cells above and outside of the dotted line;
Figure 9A) demonstrated a significant increase in proliferat-
ing cells with an average proportion of double positive cells
of 22% and 70% in the 50-mismatch vs EPAS1 morpholino
targeted embryos, respectively (P .029; Figure 9A,B).
FIGURE 4 CRISPR/Cas9 mediated knockout of hypoxia inducible factor (HIF)-2α delays embryogenesis. A, Immunofluorescent
staining for HIF-2α in embryos electroporated with control (CTRL) or HIF-2α (EPAS1.2) targeting gRNAs. Arrowheads denote GFP+ cells
lacking HIF-2α in knockout embryos. Sections from trunk. B, Relative mRNA expression measured by qRT-PCR. WT, wild-type HH18
embryos. C,D, Determination of developmental age 36 hours postelectroporation with a nontargeting (CTRL) gRNA compared to three
different gRNAs targeting EPAS1 (EPAS1.1, EPAS1.2, EPAS1.3) as assessed by head- and tail morphology (converted to Hamburger
Hamilton [HH] stages, C. Number of embryos analyzed were n = 14 [CTRL], n = 10 [EPAS1.1], n = 14 [EPAS1.2], and n = 14 [EPAS1.3]) or
by counting somites ex ovo. (D, Number of embryos analyzed were n = 8 [CTRL], n = 13 [EPAS1.1], and n = 14 [EPAS1.3].) Statistical
significance was determined by one-way analysis of variance (ANOVA), comparing nontargeting CTRL to each individual EPAS1 gRNA.
E-G, Relative mRNA expression of trunk neural crest, E, neural crest, F, and cranial neural crest, G, associated genes in dissected trunk axial
level derived neural tube tissue, measured by qRT-PCR 36 hours postelectroporation. Data presented as mean of n = 2 biologically
independent repeats, error bars denote SEM, B,E-G. Statistical significance was determined by two-sided student's t test, comparing
nontargeting CTRL with each individual EPAS1 gRNA
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After overexpression of HIF-2α, real-time EdU incor-
poration demonstrated that cells with increased expres-
sion of HIF-2α, similar to HIF-2α knockdown cells,
became highly proliferative with an average proportion
of double positive cells of 11% and 52% in the control
and HIF-2α overexpressing embryos, respectively (P .011;
Figure 9C,D). We conclude that neural crest prolifera-
tion, embryonic development and migration is highly
sensitive to dysregulated expression of HIF-2α suggesting
that levels must be strictly controlled for proper develop-
ment (Figures 3B-E, 4C-G, 5A-F, 6A-E, and 7A-C).
2.10 | HIF-2α downregulation enhances
self-renewal capacity of trunk NC cells
Neural crest-derived crestosphere cultures24,25 enable
studies on stemness properties of neural crest cells
in vitro. Therefore, we examined EPAS1 expression in
crestosphere cultures, in which multipotent neural crest
cells can be maintained in a stem cell-like state
in vitro.25,26 Comparing crestosphere cultures derived
from trunk vs cranial axial levels (respective axial identi-
ties have been extensively characterized in References 25
FIGURE 5 Dysregulation of hypoxia inducible factor (HIF)-2α expression affects migration of trunk neural crest cells. A-E,
Immunostaining of HNK1 (red) marking migrating crest cells in one-sided electroporated embryos (right side). Electroporated cells
(nontargeting CTRL gRNA, A, gRNA #2 targeting EPAS1 (EPAS1.2; B), 50-mispair morpholino, D, or EPAS1 morpholino, E) are seen in
green. DAPI was used to counterstain nuclei. Embryo sections from trunk axial level are from 36 hours, A,B, or 44 hours, D,E,
postelectroporation. Arrowheads highlight the difference in HNK1+ area in control vs electroporated side. C,F, Quantification of area
positive for HNK1. Area on electroporated side in EPAS1.2, B, or EPAS1 morpholino, E, embryos was normalized to that of respective
control side. Data are presented as mean ± SEM. Statistical significance was calculated using one-way analysis of variance (ANOVA)
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and 26), showed that EPAS1 was enriched in trunk
crestospheres (Figure 9E).
We further established trunk crestospheres from
embryos previously electroporated with a control gRNA
construct or two different gRNAs targeting EPAS1
(EPAS1.1 and EPAS1.2). Primary sphere assays demon-
strated that cells with dysregulated HIF-2α levels had an
increased ability to form new spheres when seeded as single
cells (1 cell/well; Figure 9F-G). In addition, crestosphere
cultures derived from embryos electroporated with the
EPAS1.2 construct formed larger spheres compared to their
control counterparts (Figure 9H).
2.11 | RNA sequencing after loss of HIF-
2α identifies downstream genes associated
with invasion, growth arrest, and
developmental regulation
To investigate global gene expression changes in cells
with dysregulated levels of HIF-2α, we performed loss
of function experiments at premigratory stages of
trunk neural crest development (HH10+/HH11 in avian
embryos) using the splice targeting morpholino as
above. Neural tubes from trunk region were dissected
24 hours postelectroporation (at stage HH16, when
trunk neural crest cells are in the premigratory to early
delaminating phase) and subsequently analyzed these
by RNA sequencing. Correlation plot of all genes
from the dataset demonstrated that HIF-2α knockdown
cells indeed differ from those injected with control scram-
bled morpholino (spearman P > .96; Figure 10A).
Setting a cut-off at P < .005 and removing all hits that
were not annotated (NA), identified 97 genes of interest
(Figure 10B). The top 10 genes downregulated and
upregulated (assessed by log2 fold differences in expres-
sion) by knockdown of HIF-2α are summarized in
Figure 10C, while the complete list of these 97 genes can
be found in Table 1. RNA sequencing results were vali-
dated by analyzing selected genes from the top list by
qPCR using the samples assessed for neural crest specific
gene expression (Figure 3D,E). Genes analyzed by qPCR
FIGURE 6 Overexpression of hypoxia inducible factor (HIF)-2α reflects the knockdown phenotype. A, Hamburger Hamilton
(HH) staging of embryos 24 hours postelectroporation with a control (pCI-CTRL) or EPAS1 overexpression construct (pCI-EPAS1),
determined by head- and tail morphology. Number of embryos analyzed were n = 16 (CTRL), n = 20 (EPAS1). Statistical significance was
determined by one-way analysis of variance (ANOVA). B, Immunostaining of HNK1 (green) marking migrating crest cells in one-sided
electroporated embryos (right side). Electroporated cells (CTRL or EPAS1) are seen in red. DAPI was used to counterstain nuclei. Embryo
sections from trunk axial level are taken 48 hours postelectroporation. C, Quantification of area positive for HNK1. Area on electroporated
side in pCI-EPAS1 embryos was normalized to that of respective control side. Data are presented as mean ± SEM. Statistical significance was
calculated using one-way ANOVA. D, In situ hybridization for TFAP2B in whole embryos postelectroporation with pCI-CTRL vs pCI-EPAS1
constructs. E, Sections at trunk axial level of embryos in, D
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followed the RNA sequencing predicted effect from HIF-
2α knockdown (Figure 10D).
Gene set enrichment analysis (GSEA) on the RNA
sequencing data demonstrated that two out of the top five
processes connected to disease were cancer and tumor
morphology (with 29 and 8 out of 97 molecules, respec-
tively; Figure 11A). Deeper analysis of tumor morphology
showed that genes associated with invasion of tumor cells
and size and volume of tumor were particularly enriched,
that is, these associated genes linked to specific disease
categories are not due to random chance but are statisti-
cally significant (P < .05) (Figure 11A,B). Consistent with
in vivo data, we identified cellular movement as one of
the top molecular and cellular functions affected, with
invasion as well as migration of tumor cells and EMT as
predicted downstream pathways (Figure 11A,B). GSEA
also revealed enrichment of genes associated with embry-
onic development and in particular arrest in embryo
growth (Figure 11A,B). We conclude that the predicted
cellular functions derived from our RNA sequencing
experiment overlap with in vivo data (cf. Figure 11 with
Figures 3-9). In terms of signaling pathways, top net-
works from the RNA sequencing data showed enrich-
ment of the ephrin receptor- and phosphatidylinositol
3-kinase (PI3K) signaling pathways (Figures 11C and 12,
with full list of gene ontology enriched processes in
Table 2). We have previously shown that the PI3K path-
way regulates HIF-2α specifically via mTORC2 and in
addition is a promising treatment strategy using a triple
PIM/PI3K/mTOR inhibitor in trunk neural crest-derived
tumor form neuroblastoma.27,28 Thus, this would be an
interesting mechanism to investigate further.
FIGURE 7 Overexpression
of hypoxia inducible factor
(HIF)-2α alters neural crest gene
expression. A-D, Relative mRNA
expression of trunk neural crest
specific, A, neural crest, B,
cranial neural crest, C, and
EPAS1, D, genes in dissected
neural tube tissue derived from




measured by qRT-PCR 24 hours
postelectroporation. Data
presented as mean of n = 2
biologically independent
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2.12 | HIF-2α, BMP signaling, and EMT
process are predicted upstream regulators
of embryo growth
Given the effects we observed on embryonic development
in vivo, we mapped potential upstream regulators of
arrest in embryo growth (one of the identified top pro-
cesses by RNA sequencing data). As expected, most genes
were transcription factors localized in the nucleus
(Figure 13). Connecting and validating the in vivo data
and RNA sequencing downstream analyses, EPAS1 itself
was identified as one of the upstream genes regulating
this process (Figure 13). Further, among the predicted
upstream regulators of arrested growth, genes associated
with stem cells, BMP signaling, and EMT were highly
enriched (Tables 3 and 4).
Dividing the hits from RNA sequencing data that
overlap with genes enriched for migration of tumor cells
revealed a large subset of genes that encode plasma
membrane associated- or are secreted proteins (Figure 14).
Several of these overlapping genes were among the 97 sig-
nificantly differentially expressed (with cut-off P < .005),
suggesting a close regulatory relationship between HIF-2α
and migration, potentially mediated by secreted extrinsic
cues and/or intercellular signaling, at least during these
time points of development.
2.13 | CDX2 and HNF1B are predicted
mediators of observed in vivo phenotypes
Two other predicted genes upstream of arrested embryo
growth were CDX2 and HNF1B, which were among the
97 significantly differentially expressed genes (DEGs) in the
RNA sequencing data (Figures 10C and 13). Deeper analy-
sis of these genes revealed autocrine signaling as well as an
interconnected regulation between the two (Figure 15).
EMT-related genes ZEB2 and SNAI1 were negatively
regulated by both of these genes (Figure 15). In addition,
CDX2 was predicted to regulate MYCN, a transcription fac-
tor commonly amplified in aggressive neuroblastoma
(Figure 15). Both CDX2 and HNF1B were predicted to be
upstream regulators of HIF-2α, as well as downstream tar-
gets. The majority of predicted EPAS1 upstream regulators
were indeed transcription factors, and we observed an
enrichment for stem cell associated genes, which is in con-
junction with previous reports on relationships between
HIF-2α and, for example, OCT4 and NANOG29 (Table 5).
FIGURE 8 Sox9 expression is not affected by dysregulated levels of Hypoxia inducible factor (HIF)-2a. A-C, Immunostaining of Sox9
(red) in one-sided electroporated embryos (right side). Electroporated cells (nontargeting gRNA [CTRL, A] or gRNA #1 [EPAS1.1, B] and #3
[EPAS1.3, C] targeting EPAS1) are seen in green. DAPI was used to counterstain nuclei. Embryo sections from trunk axial level are from
36 hours postelectroporation
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3 | DISCUSSION
HIF-2α has been implicated in tumor growth and is
expressed in putative cancer stem cells of several tumors
including pediatric neuroblastoma, a tumor form likely
arising from trunk neural crest. The four published HIF-
2α knockout mice models differ in their resulting
phenotype,17,30-33 but one thing they share is that HIF-
2α−/− mice display defects in SNS development—a tissue
arising from trunk neural crest. Despite this, little has
FIGURE 9 Hypoxia inducible factor (HIF)-2α affects proliferation and self-renewal capacity. A-D, Embryo sections from trunk axial
level. Proliferating EdU+ cells are green and electroporated cells (morpholinos, A; pCI-CTRL and pCI-EPAS1, C) are red. DAPI
counterstains nuclei. Only construct targeted neural crest cells (above and outside of dotted line) were quantified (n = 82 [50-mispair
morpholino] and n = 303 [EPAS1 morpholino], B); n = 211 (pCI-CTRL) and n = 139 (pCI-EPAS1), D. Statistical significance calculated
using one-way analysis of variance (ANOVA). E, Relative mRNA expression of EPAS1 in crestosphere cells established from cranial or trunk
axial level measured by qRT-PCR. Expression is presented as mean of n = 4 (cranial) or n = 3 (trunk) biological replicates and error bars
represent SEM. Statistical significance calculated using two-sided student's t test. F,G, Primary sphere assay of crestospheres established from
embryos previously electroporated in ovo with non- (CTRL) or EPAS1 (EPAS1.1, F, EPAS1.2, G, targeting gRNAs. One cell/well, n = 10
wells/group). Number of spheres were manually counted after 1 week. Statistical significance was calculated by one-way ANOVA. H, Size of
spheres formed in, G. Manual measurements using the ImageJ software to convert to factual unit (μm). Statistical significance was
determined by one-way ANOVA. Inserted photographs of representative spheres from each group
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FIGURE 10 RNA sequencing identifies hypoxia inducible factor (HIF)-2α downstream genes. A,B, Hierarchical clustering of
significantly differentially expressed genes (DEGs; cut-off P < .005) identified from RNA sequencing comparing 50-mispair and EPAS1
morpholino samples. C, List of the top 10 upregulated and top 10 downregulated genes from the RNA sequencing data. D, Relative mRNA
expression as measured by qPCR. Samples from Figure 3D,E. EPAS1 morpholino sample was normalized to that of 50-mispair control to
obtain fold change in expression
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TABLE 1 Full list of the 97 significantly (P < .005) DEGs between 50-mispair and EPAS1 morpholino samples identified by RNA
sequencing
Gene_stable_ID Gene_name log2FoldChange P-value
ENSGALG00000035219 ALB −1.117182632 .004326406
ENSGALG00000007599 AMER1 −0.405238741 .000373362
ENSGALG00000002723 ANKS1A −0.620471912 .002221987
ENSGALG00000020876 AOX2 −1.096918485 .00085007
ENSGALG00000000220 APC −0.47416616 .000273889
ENSGALG00000026364 ASAH1 0.421872055 .002627088
ENSGALG00000002558 ASL1 −2.269756179 .000254935
ENSGALG00000014234 ATXN10 0.477982264 .001858816
ENSGALG00000009642 AVEN 0.319184758 .002524998
ENSGALG00000039595 BTBD11 1.074785502 .000312368
ENSGALG00000040463 CABP7 −1.850580177 .003025143
ENSGALG00000012095 CCDC198 −1.657954928 .00269933
ENSGALG00000006787 CCDC71 −0.470629203 .002673943
ENSGALG00000015395 CD200L −2.132229985 .000154209
ENSGALG00000000608 CDH1 −1.307331812 .000773978
ENSGALG00000034983 CDX2 −2.4394251 8.25E-05
ENSGALG00000004687 CENPP 0.424109009 .000169658
ENSGALG00000037504 CFAP36 0.393170817 .00331114
ENSGALG00000004903 CHST8 2.680876707 .004291268
ENSGALG00000026862 CLDN1 −1.995178284 .00010847
ENSGALG00000007025 CPNE8 1.148105385 .004533116
ENSGALG00000001169 CRB2 −0.810451518 .001196479
ENSGALG00000005657 CRHR2 −0.937081004 .004656735
ENSGALG00000042454 DCDC2 −3.035920312 .003127781
ENSGALG00000011274 DCN 0.981364002 .002209936
ENSGALG00000014700 DHX29 −0.444692933 .003215344
ENSGALG00000032937 DLGAP2 1.296643213 .003793901
ENSGALG00000040529 DLX3 −5.237610938 .001107996
ENSGALG00000012156 DPP10 1.123811132 .001713737
ENSGALG00000015403 EPHA3 0.860641014 .001951451
ENSGALG00000004741 EPHB2 −0.418815561 .001893072
ENSGALG00000003126 ERBB4 −1.15424847 .001506512
ENSGALG00000031076 ESRP1 −1.882592181 .001558762
ENSGALG00000008332 F2 −1.908762077 .001551013
ENSGALG00000041153 FAM109A −1.215286589 .004594595
ENSGALG00000013503 FAM149A 0.797519339 .004470883
ENSGALG00000011099 FAP 1.014306518 .00201386
ENSGALG00000008753 FBXO48 1.321581752 .002069094
ENSGALG00000010316 FRAS1 −0.558639554 .001060929
ENSGALG00000031487 FSTL4 1.704294412 .004365436
ENSGALG00000007047 GAL 2.641577626 .001941927
ENSGALG00000028191 GLCE −0.598344895 .000897534
(Continues)
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TABLE 1 (Continued)
Gene_stable_ID Gene_name log2FoldChange P-value
ENSGALG00000010350 GPATCH2L −0.487810446 7.98E-06
ENSGALG00000041556 GPATCH8 −0.317242944 .003590909
ENSGALG00000037687 GRHL2 −1.807620277 .003321608
ENSGALG00000016124 HADH 0.25603248 .003556043
ENSGALG00000005504 HNF1B −2.281631746 .00080264
ENSGALG00000012009 JKAMP 0.382527526 .003435274
ENSGALG00000019718 KRT15 1.634804647 .000760169
ENSGALG00000030710 L3MBTL1 −0.530953634 .001495242
ENSGALG00000036022 LIN28A −1.38546498 .000196313
ENSGALG00000012801 LY86 1.615548567 .003593197
ENSGALG00000002379 MRPS17 0.239466428 .001783389
ENSGALG00000007661 MYCBPAP −0.506429259 .004333666
ENSGALG00000031450 MYO7A −0.679727815 .003592535
ENSGALG00000002131 NPRL2 −0.499654709 .003409913
ENSGALG00000004245 NUDT1 0.510897854 .00012546
ENSGALG00000013348 OTUD7B −0.376188595 .001170227
ENSGALG00000012869 OVAL −2.685319715 .002991518
ENSGALG00000042645 PARD3B −0.501189766 1.96E-06
ENSGALG00000009378 PDGFC 0.796369213 .001886551
ENSGALG00000002963 PID1 1.07251355 .003711941
ENSGALG00000001264 PLXNA2 −0.787868279 .002137423
ENSGALG00000006409 PODXL −0.886446619 .004450686
ENSGALG00000026210 POMK 0.337221928 .003042971
ENSGALG00000017046 POSTN 1.786031417 .004588475
ENSGALG00000016702 PPP2R3B 0.391820083 .003451236
ENSGALG00000010052 PPP2R3C 0.399540693 .001962875
ENSGALG00000015113 PTAR1 −0.539683505 .001225948
ENSGALG00000010053 PTPRF −0.480481292 .003964241
ENSGALG00000007155 RMI2 1.140626082 .001382943
ENSGALG00000031018 RNF165 −1.03414841 .001120092
ENSGALG00000015311 RNF38 −0.537721584 .003385081
ENSGALG00000006486 RPP30 0.342750725 .004109447
ENSGALG00000046226 SCARB1 2.040797789 .00121797
ENSGALG00000004424 SEC16B −1.1085265 .000492445
ENSGALG00000037863 SEC61G 0.557099237 .002778043
ENSGALG00000042051 SETD2 −0.308714867 .000307483
ENSGALG00000004140 SH3BP4 −0.494833722 .001195274
ENSGALG00000001644 SIN3A −0.319985031 .001157216
ENSGALG00000002957 SLC12A3 −2.700635689 .000223534
ENSGALG00000010117 SLC25A21 0.766964291 .00238367
ENSGALG00000015846 SNAP91 1.1198235 .000304383
ENSGALG00000034528 SNTB1 1.15258033 .003458367
ENSGALG00000036932 SPEN −0.388461063 .00077178
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been known about HIF-2α expression and function dur-
ing normal trunk neural crest development following
delamination from the neural tube. Here, we show that
the HIF-2α protein is expressed in trunk neural crest cells
and sympathetic neuroblasts during normal embryogene-
sis in three different species, human, mouse and avian
and examine its function using the chick embryo as a
model amenable to experimental manipulations. Compa-
rable data across human, mouse, and avian tissue suggest
that cross-species interpretation of further results is valid.
HIF-2α is canonically regulated by oxygen-dependent
prolyl hydroxylases and degraded at high oxygen concen-
trations. However, it has become clear that mechanisms
of regulation and actions of HIF-2α is much more com-
plex, and that HIF-2α, for example, can be stabilized at
physiological oxygen levels in embryonic and adult as
well as tumor tissues. To investigate the oxygen availabil-
ity in the neural tube at trunk axial level during develop-
ment, we measured oxygen saturation within the neural
tube using a microsensor. Oxygen levels slowly decrease
within this tissue over time (HH10-HH24), with the
exception of a temporary rise at HH19. This temporal
change is most likely due to relaxed oxygen respiration
and a possible temporary reduction in cell proliferation
or aerobic respiration that lead to less O2 being consumed
during this particular developmental stage. We speculate
that these changes are coordinated and necessary in the
overall developmental program, and that the increase of
O2 at HH19 therefore highlights that during development
both access to oxygen and to molecular regulation of
cell behavior—such as that of HIF-2α, for example,—
are involved in the true breed of cells and tissue. Techni-
cally impressive papers published in the 1980s measured
oxygen concentrations in the organ primordia in
the developing chick embryo using microelectrodes,
and demonstrated low tissue PO2,
34,35 supporting our
observed decrease in oxygen over time. Our previous data
on HIF-2α noncanonical cytoplasmic localization and
expression at physiological oxygen levels in tumor
tissue,6,7,9 together with our results presented here dem-
onstrating dual nuclear and cytoplasmic localization dur-
ing trunk neural crest development support the need of
further research on the complexity of HIF-2α.
We examined the functional role of HIF-2α in trunk
neural crest development by using overexpression and
knockdown approaches. Either knockdown or over-
expression of HIF-2α affected several functions critical
for proper embryonic development. Not only do embryos
with dysregulated HIF-2α have developmental delays as
compared to their control counterparts, but they also
exhibit altered neural crest gene expression profiles. Con-
sistent with observed in vivo effects, RNA sequencing
data demonstrate a global genome level change after loss
of HIF-2α, with enrichment of genes involved in invasive
behavior and growth arrest. Furthermore, we observed
altered trunk neural crest migratory patterns as well as
enhanced proliferative capacity of trunk neural crest cells
in vivo, as well as in our RNA sequencing data.
Knockdown and overexpression of HIF-2α confer the
same biological phenotypes of trunk neural crest cells
in vivo. We hypothesize that this is due to the importance
of keeping HIF-2α levels tightly regulated during devel-
opment, rather than requiring particularly low or high
expression. This is in line with the function and strict reg-
ulation of several other transcription factors involved in
neural crest cell development and migration.
Despite extensive proliferation of trunk neural crest
cells with dysregulated HIF-2α expression, the embryos
as a whole develop at a slower pace than their control
counterparts. This could be explained by either, or both,
TABLE 1 (Continued)
Gene_stable_ID Gene_name log2FoldChange P-value
ENSGALG00000039497 TFAP2E −3.18357506 .000779405
ENSGALG00000015184 TLE4Z1 −0.444405062 .001437148
ENSGALG00000010896 TMEM161B −0.546018409 .001173125
ENSGALG00000001459 TNNC1 1.720938851 .003720707
ENSGALG00000020523 TOPORS −0.473621698 .003381281
ENSGALG00000010152 TSPAN8 −3.77045907 .002947966
ENSGALG00000012259 UBXN4 0.264129274 .004330698
ENSGALG00000043106 WDR17 −1.478943795 .001766045
ENSGALG00000016558 VEGFD 1.266960804 .004105067
ENSGALG00000011283 ZNF385D 1.483429288 .004653997
ENSGALG00000001518 ZNF750 −1.901269846 .002582973
Abbreviation: DEGs, differentially expressed genes.
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of the following processes. First, several papers have
reported that differences in oxygen levels severely affects
embryonic growth.12,13,34 Considering that physiological
HIF-2α creates a so-called pseudohypoxic phenotype,36
perturbation of HIF-2α expression levels could be a con-
tributing factor to the decreased growth rate. Secondly,
cell division of trunk neural crest cells is in general lim-
ited during their active migratory phase. The observed
embryonic delay relative to increased trunk neural crest
cell proliferation may be the result of a skewed cell
division to migration ratio, with increased proliferation
possibly causing a failure in timely cell migration.
The capacity to self-renew is an important feature of
stem-like cells. Our data suggest that EPAS1 knockout cells
exhibit enhanced self-renewal, in line with observations
in neuroblastoma cells with aberrant HIF-2α expression
which are more immature, stem cell- and neural crest-like.7
In addition, crestospheres formed by HIF-2α dysregulated
single cells were on average larger, a sign of enhanced pro-
liferative capacity in agreement with our EdU results.
FIGURE 11 Gene set enrichment analysis identifies hypoxia inducible factor (HIF)-2α downstream affected processes. A, Top five hits
(P < .05) in the respective categories “Disease and Disorders,” “Molecular and Cellular Functions,” and “Physiological System Development
and Function” identified by hypothesis-free/exploratory analysis of the 97 differentially expressed genes (DEGs) using IPA (Fishers exact test
for the range of P-value calculation). B, Deeper analysis of processes identified in, A. C, Selected list of enriched cellular processes from
Panther analyses. Complete list in Table 2
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With regard to kinase signaling, RNA sequencing data
revealed enrichment of two signaling pathways, the ephrin
receptor- and PI3K pathways. This suggests that environ-
mental signaling cues may be influencing trunk neural
crest behavior. Of note, we have recently identified that
PI3K-mTORC2 regulates HIF-2α expression and functions
as a valid treatment target in neuroblastoma.27,28 Genes
associated with migration of tumor cells mainly encode for
plasma membrane and secreted proteins, including several
members of the matrix metalloproteinase (MMP) family.
MMPs promote invasion and migration by degrading
components of the extracellular matrix and have been
shown to be regulated by HIF-2α in several different
tumor forms,37,38 further reinforcing a possible connection
between HIF-2α, trunk neural crest cells and invasive
migratory behavior.
The stem cell gene POU5F1, more commonly known
as Oct4, is driven by HIF-2α in immature cells during
FIGURE 12 Gene set enrichment analysis identifies key molecules. Top network composed by analyzing significantly differentially
expressed genes (DEGs) from RNA sequencing data. The shape of molecules and their meaning, that is, correspondence to protein family,
and so forth, is found here: http://qiagen.force.com/KnowledgeBase/KnowledgeIPAPage?id=kA41i000000L5rTCAS. As an example, the
diamond-shaped molecules correspond to enzymes, oval standing shapes should be read as transmembrane receptors, and lying oval shapes
are transcription regulators. Green nodes indicate downregulated molecules. The intensity of the color reveals the strength of the expression,
that is, the stronger the color the more significant. The dashed lines indicate an indirect interaction between molecules in the network
whereas solid lines are direct interactions. The solid arrow explains the direction of the indicated interaction. A line, solid, or dashed,
without an arrowhead indicate an RNA-RNA interaction
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TABLE 2 Complete list of processes identified by PANTHER analysis
Fold enrichment P-value
Cytolysis by symbiont of host cells (GO:0001897) > 100 1.44E-04
Hemolysis in other organism involved in symbiotic interaction (GO:0052331) > 100 1.44E-04
Cytolysis in other organism involved in symbiotic interaction (GO:0051801) >100 2.30E-06
Maintenance of mitochondrion location (GO:0051659) >100 1.44E-04
Trans-synaptic signaling by trans-synaptic complex, modulating synaptic transmission
(GO:0099557)
>100 1.44E-04
Hemolysis in other organism (GO:0044179) >100 1.44E-04
Hemolysis by symbiont of host erythrocytes (GO:0019836) >100 1.44E-04
Killing of cells in other organism involved in symbiotic interaction (GO:0051883) >100 4.01E-06
Disruption of cells of other organism involved in symbiotic interaction (GO:0051818) >100 4.01E-06
Cytolysis in other organism (GO:0051715) >100 4.01E-06
Multiorganism cellular process (GO:0044764) 60.51 3.21E-05
Cytolysis (GO:0019835) 55.01 4.07E-05
Disruption of cells of other organism (GO:0044364) 50.43 5.06E-05
Killing of cells of other organism (GO:0031640) 50.43 5.06E-05
Axonal fasciculation (GO:0007413) 40.34 8.99E-05
Neuron projection fasciculation (GO:0106030) 40.34 8.99E-05
Ephrin receptor signaling pathway (GO:0048013) 26.03 2.58E-05
Positive regulation of PI3K signaling (GO:0014068) 17.17 1.16E-04
Positive regulation of cellular protein localization (GO:1903829) 7.55 4.91E-05
Regulation of cellular protein localization (GO:1903827) 7.09 5.64E-07
Regulation of cellular localization (GO:0060341) 4.52 1.54E-05
Cell migration (GO:0016477) 4.37 2.16E-05
Cell motility (GO:0048870) 3.98 1.11E-04
Regulation of protein localization (GO:0032880) 3.94 5.84E-05
Localization of cell (GO:0051674) 3.94 5.84E-05
Locomotion (GO:0040011) 3.73 2.39E-05
Regulation of cell differentiation (GO:0045595) 3.43 2.27E-06
Regulation of response to stimulus (GO:0048583) 3.01 1.48E-05
Regulation of biological process (GO:0050789) 2.61 3.94E-05
Regulation of cellular component organization (GO:0051128) 2.57 4.79E-05
Regulation of multicellular organismal process (GO:0051239) 2.55 1.41E-05
Positive regulation of cellular process (GO:0048522) 2.33 1.37E-05
Positive regulation of biological process (GO:0048518) 2.27 1.36E-05
Negative regulation of cellular process (GO:0048523) 2.25 7.91E-05
Negative regulation of biological process (GO:0048519) 2.09 5.55E-06
Cytolysis by symbiont of host cells (GO:0001897) 2.06 2.05E-06
Regulation of multicellular organismal development (GO:2000026) 2.04 2.70E-05
Regulation of developmental process (GO:0050793) 2.03 8.99E-05
Anatomical structure development (GO:0048856) 2.02 6.47E-05
Multicellular organism development (GO:0007275) 1.98 3.99E-05
Developmental process (GO:0032502) 1.97 6.32E-05
Positive regulation of metabolic process (GO:0009893) 1.85 3.35E-05
Regulation of metabolic process (GO:0019222) 1.47 1.21E-04
Positive regulation of cellular metabolic process (GO:0031325) >100 1.44E-04
Abbreviation: PI3K, phosphatidylinositol 3-kinase.
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development.29 We found that Oct4 is predicted to be
upstream of arrested embryo growth, but also an
upstream regulator of EPAS1 itself. One of the EPAS1
target molecules connecting Oct4 and HIF-2α is CDX2,
which in turn is upstream of EPAS1 as well as arrested
embryo growth (Figures 13 and 15, and Tables 4 and 5).
FIGURE 13 Transcription factor dominance in regulating arrested embryo growth. Deeper analysis of potential upstream regulators of
the “arrest in embryo growth” process identified in Figure 11A,B. The shape of molecules and their meaning, that is, correspondence to
protein family, and so forth, is found here: http://qiagen.force.com/KnowledgeBase/KnowledgeIPAPage?id=kA41i000000L5rTCAS. As an
example, the diamond-shaped molecules correspond to enzymes, oval standing shapes should be read as transmembrane receptors and lying
oval shapes are transcription regulators. Green nodes indicate downregulated molecules. The intensity of the color reveals the strength of the
expression, that is, the stronger the color the more significant
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CDX2 is indeed one of the major players involved in medi-
ating the HIF-2α driven effects on embryonic development.
Considering that CDX2 is an early trunk neural crest
marker,22 a possible explanation for delayed embryonic
development might also be halted trunk neural crest com-
mitment; however, this requires further investigation.
These findings contribute to understanding a complex
regulatory network involved in mediating trunk neural
crest development. We posit that the cancer associated pro-
tein HIF-2α may play a central role in embryonic growth,
global trunk neural crest cell gene expression, migration,
proliferation, and self-renewal features within this net-
work. These findings are in line with data from Ko et al
showing that HIF-2α protects neural progenitor cell sur-
vival and differentiation in zebrafish CNS development.39
In conclusion, our results highlight the importance of strict
control of HIF-2α levels for maintenance of normal embry-
onic growth and trunk neural crest development.
4 | EXPERIMENTAL PROCEDURES
4.1 | Chick embryos
According to Swedish regulations (Jordbruksverkets
föreskrift L150, §5) work on chick embryos younger than
embryonic day 13 do not require Institutional Animal
Care and Use Committee oversight.
4.2 | Human and mouse fetal tissue
Human fetal tissue (ethical approval Dnr 6.1.8-2887/2017,
Lund University, Sweden) was obtained from elective abor-
tions. Tissue samples were dissected in custom-made hiber-
nation medium (Life Technologies, Carlsbad, California)
and fixed in 4% formaldehyde overnight. Following a sucrose
gradient, embryos were embedded in gelatin for transverse
sectioning at 12 μm (ew5) or 7 μm (ew6) using a cryostat.
4.3 | Cell culture
The human neuroblastoma cell line SK-N-BE(2)c (ATCC;
Manassas, Virginia) was cultured in MEM supplemented
with 10% fetal bovine serum and 100 units penicillin and
10 μg/mL streptomycin. As part of our laboratory rou-
tines, all cells were maintained in culture for no more
than 30 continuous passages and regularly screened for
mycoplasma. SK-N-BE(2)c cells were authenticated by
SNP profiling (Multiplexion, Germany).
4.4 | Embryos and perturbations
Chick embryos were acquired from commercially pur-
chased fertilized eggs and incubated at 37.5C until
TABLE 3 Selected genes identified as potential upstream
regulators of arrested embryo growth. Genes associated with stem
cells, BMP signaling, and EMT were particularly enriched





SOX2 Transcription regulator 3,72E-16
POU5F1/OCT4 Transcription regulator 5,29E-16
E2F4 Transcription regulator 2,66E-12
KLF4 Transcription regulator 2,61E-11
NANOG Transcription regulator 2,81E-07
EZH2 Transcription regulator 2,69E-08
GLI1 Transcription regulator 1,68E-05
NOTCH1 Transcription regulator 2,31E-03
KLF2 Transcription regulator 3,00E-03
SALL4 Transcription regulator 1,67E-02
HEY1 Transcription regulator 1,97E-02
KLF6 Transcription regulator 2,66E-02
HEY2 Transcription regulator 3,57E-02
BMI1 Transcription regulator 2,84E-04





BMP4 Growth factor 5,74E-11
BMP2 Growth factor 2,69E-03
BMP10 Growth factor 5,06E-03
BMP6 Growth factor 1,17E-02
SMAD2 Transcription regulator 5,66E-09
SMAD7 Transcription regulator 8,82E-06
SMAD4 Transcription regulator 5,43E-05
SMAD3 Transcription regulator 1,38E-03





SNAI1 Transcription regulator 8,22E-04
ZEB2 Transcription regulator 1,44E-03
TWIST1 Transcription regulator 3,00E-03
ZEB1 Transcription regulator 1,10E-02
LEF1 Transcription regulator 2,03E-02
NODAL Growth factor 2,13E-02
Abbreviation: EMT, epithelial-to-mesenchymal transition.
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TABLE 4 Complete list of genes identified as potential upstream regulators of arrested embryo growth
Upstream of arrest in embryo growth
Upstream regulator Molecule type P-value of overlap Target molecules in dataset





























E2F4 Transcription regulator 2.66E-12 BECN1,CDK2,DDX11,GINS1,HSP90B1,MCL1,
MCM10,MYCN,NASP,RAD51,RB1,RBBP8,
RBL2,SHH,SMARCA5,TOPBP1,TP53,UHRF1








KLF4 Transcription regulator 2.61E-11 ACVR1,ACVR2A,CDX2,DLX3,EOMES,FLT1,
GATA4,HAND1,Macf1,NF1,NOTCH1,OTX2,
SMAD4,TDGF1,THBD,TP53,TXNRD1,WLS
BMP4 Growth factor 5.74E-11 ACVR2A,ACVR2B,CDH5,CDK2,CDKN2A,CDX2,
DLX3,MYCN,PTCH1,SHH,SNAI1,SPINT1,
TAL1,TBX5,TDGF1,TP53
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TABLE 4 (Continued)
Upstream of arrest in embryo growth
Upstream regulator Molecule type P-value of overlap Target molecules in dataset




HDAC1 Transcription regulator 2.55E-09 ARC,CDK2,CDKN2A,COMMD3-BMI1,EHMT2,
FLT1,MCM10,NASP,PCYT1A,SLC8A1,SNAI1,
TAL1,TBX5,TP53,UHRF1,USP7
FOXM1 Transcription regulator 3.15E-09 ATF2,CDK2,CDKN2A,COMMD3-BMI1,FLT1,
MYCN,PLK4,PTCH1,SNAI1,TP53,XRCC1,ZEB2
RNF2 Transcription regulator 3.34E-09 CDKN2A,CDX2,COMMD3-BMI1,EOMES,
FOXA2,GATA4,HAND1,PCGF2,TP53
GMNN Transcription regulator 3.98E-09 ACVR1,ACVR2A,CDX2,EOMES,HAND1,Macf1,
SMAD4,TP53,TXNRD1,WLS







SMAD2 Transcription regulator 5.66E-09 BECN1,CDH5,CDKN2A,CDX2,FLT1,GSC,RAC1,
SMAD2,SMAD4,SNAI1
SOX1 Transcription regulator 1.98E-08 ACVR1,ACVR2A,CDX2,EOMES,HAND1,Macf1,
SMAD4,TXNRD1,WLS
SP110 Transcription regulator 2.23E-08 ATF2,DICER1,FLII,GNA13,MCL1,MYCN,
PLCG1,RAC1,RARRES2,SMAD2,SOX4
EZH2 Transcription regulator 2.69E-08 CDK4,CDK6,CDKN2A,CDX2,CUL1,DNMT1,
EOMES,EP300,EZH2,FGF4,FLT1,GATA4,
KRAS,RNASEH1,SHH,SNAI1,TP53
RBL1 Transcription regulator 2.84E-08 CDK2,CDKN2A,MCM10,MTOR,MYCN,
NOTCH1,RB1,RBL2,TP53
PCGF2 Transcription regulator 2.97E-08 CDK4,CDK6,CDKN2A,CDX2,GATA4,NOTCH1,
TP53
AGT Growth factor 3.31E-08 BECN1,CASP8,CDK4,CDKN2A,FLT1,HIF1A,
KRAS,MAPK7,PARP1,RAC1,RIPK3,SLC8A1,
SOX4,TBX20,TBX5,THBD,TP53,TRPM7,ZEB2
SOX3 Transcription regulator 3.58E-08 ACVR1,ACVR2A,CDX2,EOMES,HAND1,Macf1,
SMAD4,TXNRD1,WLS
E2F3 Transcription regulator 7.82E-08 BECN1,CDK2,CDKN2A,DAG1,EZH2,KRAS,
MCM10,MYCN,RAD51,RB1,THBD,TOPBP1
HGF Growth factor 1.55E-07 ATF2,CASP8,CDK2,CDK4,CDKN2A,DDX11,
FLT1,FOXA2,GNA13,MCL1,Nrg1,PLK4,RAC1,
RAD50,RARRES2,SNAI1,THBD,TOPBP1,TP53
NANOG Transcription regulator 2.81E-07 CDK6,EOMES,FOXA2,GATA4,GSC,ISL1,MAX,
MYCN,SRRT,TP53
E2F2 Transcription regulator 2.83E-07 BECN1,CDKN2A,EZH2,MCM10,MYCN,RAD51,
TOPBP1,TP53
PTTG1 Transcription regulator 3.89E-07 HIF1A,PARP2,RAD50,RAD9B,REV3L,SNAI1,
TDG,TP53
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EIF4E Translation regulator 5.63E-07 CDK2,CDK4,CDKN2A,EP300,HIF1A,MCL1,
NRAS,RB1,SNAI1,TP53
VEGFA Growth factor 5.73E-07 CDH5,CDKN2A,EOMES,FLT1,HIF1A,LDB1,
MCL1,MYCN,NOTCH1,PARP1,SDHD,TAL1,
THBD,TP53
SRF Transcription regulator 5.80E-07 AMD1,ARC,CDK4,FLT1,GATA4,MCL1,MYL1,
RAF1,SHH,SLC8A1,SNX2,TAL1,TBP,TLN1,
VCL








SP1 Transcription regulator 9.58E-07 ABCA1,ACVRL1,CDK2,CDK4,CDK6,CDKN2A,
DLX3,FLT1,HIF1A,MCL1,MYCN,NF1,PARP1,
PCYT1A,RB1,THBD,TP53,TXNRD1,ZEB2
FOXO3 Transcription regulator 1.55E-06 ACVR1,BECN1,CASP8,CDH5,CDK4,GCLC,
HIF1A,MAX,RASA1,RBL2,SMAD4,SNAI1,
TAL1,TP53
INHBA Growth factor 1.63E-06 ACVR1,ACVR1B,ACVR2A,ACVR2B,CDK4,
FOXA2,KRAS,MCL1,SMAD2,SOX4,TAL1
NKX2-5 Transcription regulator 1.75E-06 ACACA,BMP10,GATA4,HAND1,MYCN,TBX5
CCND1 Transcription regulator 2.29E-06 CDK2,CDK4,CDK6,CDKN2A,DNMT1,GATA4,
MCM10,NOTCH1,PCYT1A,RAD51,RB1,SOX4,
TP53,UHRF1
TBX20 Transcription regulator 2.89E-06 BMP10,MYCN,TBX5
HNRNPK Transcription regulator 3.07E-06 ATF2,FGF4,G6PD,HUS1,RASA1,RB1
CDKN2A Transcription regulator 3.20E-06 AMD1,CDK2,CDKN2A,CHAF1A,CUL1,EZH2,
GNA13,KRAS,MCL1,MYCN,RB1,TP53,TSG101
PML Transcription regulator 3.48E-06 ACACA,CDK2,CDKN2A,SNAI1,SUMO2,
TOPBP1,TP53,TXN,TXNRD1
ETS1 Transcription regulator 4.81E-06 CDH5,CDK11A,CDK2,CDK6,CDKN2A,FLT1,
MCL1,PARP1,SNAI1,TP53,ZEB2




NCOA1 Transcription regulator 7.48E-06 ABCA1,CASP8,EOMES,HIF1A,HIRA,LIAS,
PDCD2,POU2F1,RB1
CITED2 Transcription regulator 8.06E-06 CDKN2A,CDX2,COMMD3-BMI1,HIF1A,PCGF2
SMAD7 Transcription regulator 8.82E-06 ACVR1,ACVR1B,ACVR2A,ACVR2B,BMPR2,
FOXA2,GATA4,RAC1,TXN
MED1 Transcription regulator 1.41E-05 ACACA,ARID1A,CDK2,CDK4,CHAF1A,MCL1,
MYCN,NF1,TP53
TEAD4 Transcription regulator 1.50E-05 CDX2,EOMES,FLT1,GATAD2A,HIF1A
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GLI1 Transcription regulator 1.68E-05 ARC,CDK2,COMMD3-BMI1,FOXA2,GATA4,
MYCN,PTCH1,SNAI1,TP53,USP7
FGF2 Growth factor 1.99E-05 ARC,CDX2,FLT1,HIF1A,HIRA,KRAS,MYCN,
NF1,NOTCH1,RAF1,RB1,SHH,SNAI1,TP53
STAT3 Transcription regulator 2.24E-05 BECN1,CDH5,CDKN2A,COPS5,DNMT1,EOMES,
FLT1,HIF1A,IHH,MCL1,NOTCH1,POU2F1,
SHH,SNAI1,THBD,TP53,USP7
CCNH Transcription regulator 2.26E-05 CDX2,COMMD3-BMI1,GATA4,HAND1
EED Transcription regulator 2.92E-05 CDKN2A,CDX2,GATA4,SHH,TBX5
SIRT1 Transcription regulator 3.16E-05 ABCA1,ATF7,CDKN2A,EP300,GATA4,HIF1A,
MGAT1,NF1,PARP1,RAC1,TAL1,THBD,TP53
HDAC2 Transcription regulator 3.22E-05 CDK2,CDKN2A,COMMD3-BMI1,MCM10,
MYCN,NASP,SLC8A1,TP53
ID1 Transcription regulator 4.10E-05 CDKN2A,FOXA2,MESP1,NOTCH1,PCGF2,
SNAI1
EIF4G1 Translation regulator 4.17E-05 HIF1A,RAD50,RAD51,TP53
NRG1 Growth factor 4.36E-05 ABCA1,CDX2,DAG1,GATA4,HIF1A,MCL1,
NOTCH1,SNAI1,SOX4,VCL
FOXO1 Transcription regulator 4.46E-05 ACACA,CASP8,CDH5,CDKN2A,EOMES,FOXA2,
HIF1A,HUS1,MYCN,PIK3C3,RBL2,SLC25A19,
SMAD4,TP53
YAP1 Transcription regulator 4.50E-05 CASP8,CDK6,CDX2,DICER1,RAD51,SMAD2,
UHRF1
FGF7 Growth factor 4.82E-05 CDK2,CDK4,CDKN2A,Nrg1,SHH,TP53
SMAD4 Transcription regulator 5.43E-05 CDH5,CDKN2A,MAPK7,MTOR,MYCN,RAC1,
SHH,SMAD2,SMAD4,SNAI1
MDM2 Transcription regulator 5.63E-05 CDK4,CDKN2A,HIF1A,MYCN,TP53,TSG101
SHOX Transcription regulator 5.87E-05 RB1,RBL2,TP53
PSMD10 Transcription regulator 5.98E-05 CDK2,CDK4,HIF1A,TP53
CEBPA Transcription regulator 6.27E-05 ACACA,APLNR,CDK4,COPS5,DLX3,FLT1,
FOXA2,HNF1B,KDM1A,MYCN,OTX2,
RARRES2,THBD,VCL
SREBF2 Transcription regulator 6.54E-05 ABCA1,ACACA,G6PD,PCYT1A,PTCH1,
RARRES2
GATA6 Transcription regulator 6.82E-05 BMPR2,CDX2,DLD,DLX3,FOXA2,GATA4,
HNF1B,OTX2,SHH
HAND1 Transcription regulator 7.07E-05 ACACA,FLT1,HAND1,NOTCH1
CCNE1 Transcription regulator 8.29E-05 CDK2,HIF1A,PCYT1A,TP53
GATA4 Transcription regulator 9.31E-05 ACACA,BECN1,CDX2,DLX3,GATA4,MYL1,
OTX2,SLC8A1,TAL1
IRF4 Transcription regulator 9.38E-05 CDK2,CDK6,CDKN2A,EOMES,FLT1,RAC1,
RAD51,XRCC1
TLX1 Transcription regulator 1.12E-04 MCL1,RAD51,RAF1,TAL1
TEAD2 Transcription regulator 1.14E-04 RAD51,TP53,UHRF1
RUNX2 Transcription regulator 1.18E-04 CSNK2B,HIF1A,IHH,ISL1,SHH,SNAI1,TLN1
ARNT Transcription regulator 1.24E-04 CDK4,FLT1,G6PD,HIF1A,Macf1,SHH,TP53
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PAX6 Transcription regulator 1.35E-04 CDK2,CDK6,EOMES,F2,ISL1,OTX2,SMAD2,
SMAD4,WLS
PITX2 Transcription regulator 1.37E-04 ATF2,EOMES,FOXA2,ISL1,SNAI1,TBX5,ZEB2
ELK1 Transcription regulator 1.51E-04 BMPR2,CDKN2A,GRK2,MCL1,SNAI1
ZIC3 Transcription regulator 1.95E-04 FOXA2,GATA4,TBX5
BRCA1 Transcription regulator 2.06E-04 EP300,NOTCH1,POU2F1,RAD51,RB1,RBL2,TBP,
TP53
YEATS4 Transcription regulator 2.43E-04 CDKN2A,TP53
TERF1 Transcription regulator 2.43E-04 CDKN2A,TP53
ELF4 Transcription regulator 2.43E-04 CDKN2A,DLX3,PIK3C3,TP53
MYCN Transcription regulator 2.66E-04 ABCA1,CDH5,COMMD3-BMI1,EZH2,FOXA2,
GATA4,MYCN,SLC25A19,TP53,ZEB2
TFDP1 Transcription regulator 2.73E-04 CASP8,CDKN2A,MYCN,TP53
BMI1 Transcription regulator 2.84E-04 CASP8,CDKN2A,CUL1,DNMT1,TP53
EGR1 Transcription regulator 3.11E-04 ARC,CASP8,FLT1,HIF1A,RB1,SHH,SNAI1,TP53
GLI2 Transcription regulator 3.50E-04 DLX3,FOXA2,GATA4,MYCN,PTCH1,SNAI1
MESP1 Transcription regulator 3.74E-04 GATA4,SNAI1,ZEB2
MAFG Transcription regulator 3.74E-04 GCLC,TP53,TXNRD1
GLI3 Transcription regulator 3.77E-04 COMMD3-BMI1,FOXA2,MYCN,PTCH1,SHH
TGFB2 Growth factor 4.08E-04 ABCA1,CDH5,CDKN2A,NOTCH1,OSR1,SMAD2
IGF1 Growth factor 4.31E-04 ABCA1,ACACA,CDK2,CDK4,CDKN2A,HIF1A,
IHH,KAT2A,MCL1,MYCN,PARP1,TP53,UBTF
MESP2 Transcription regulator 4.51E-04 GATA4,SNAI1,ZEB2
LYL1 Transcription regulator 5.37E-04 CDH5,RAPGEF2,TAL1
JARID2 Transcription regulator 5.37E-04 CDX2,HAND1,NOTCH1
RELA Transcription regulator 5.71E-04 BECN1,CASP8,CDKN2A,CTCF,EOMES,HIF1A,
HSP90B1,NOTCH1,SHH,SMAD4,SNAI1,TP53
KAT2B Transcription regulator 6.63E-04 COMMD3-BMI1,PTCH1,RB1,TP53
HR Transcription regulator 7.23E-04 AMD1,DLX3,PLCG1,UBR2
HOXA5 Transcription regulator 7.41E-04 IHH,SHH,TP53
HTT Transcription regulator 7.60E-04 ABCA1,AMD1,CDK2,DLX3,EP300,GCLC,GRK2,
GSC,HIF1A,HTT,KAT2A,MTOR,MYL1,OTX2,
RAB10,TP53
POU2F1 Transcription regulator 8.22E-04 ATF2,CDX2,FGF4,HNF1B,ISL1,POU2F1
SNAI1 Transcription regulator 8.22E-04 CDH5,CDK2,CDK4,SNAI1,THBD,ZEB2
MAFK Transcription regulator 8.59E-04 GCLC,TXN,TXNRD1
ID2 Transcription regulator 9.88E-04 CDK4,CDKN2A,EOMES,HIF1A,MAPK7,
NOTCH1,SOX4
TP73 Transcription regulator 1.02E-03 CDK2,FLT1,G6PD,MYCN,NOTCH1,RB1,SNAI1,
SPINT1,TBX5,TP53,XRCC1
TAL1 Transcription regulator 1.05E-03 AFDN,CDH5,CDK6,CDKN2A,GINS1,NOTCH1,
PLCG1,SOX4
FGF4 Growth factor 1.13E-03 DNMT1,FOXA2,SHH
ZBTB7A Transcription regulator 1.13E-03 CDK2,CDKN2A,NRAS
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STAT5A Transcription regulator 1.13E-03 CASP8,CDC7,CDK4,CDK6,EOMES,EZH2,MCL1,
SLC34A2,TP53
Rhox4b (includes others) Transcription regulator 1.19E-03 CDH5,TAL1
KLF17 Transcription regulator 1.19E-03 RB1,TP53
ID3 Transcription regulator 1.25E-03 CDKN2A,EOMES,HIF1A,MAPK7,NOTCH1,
SOX4,TP53
SMAD3 Transcription regulator 1.38E-03 CDH5,CDK4,CDKN2A,MAX,RAC1,SNAI1,
TDGF1,ZEB2
ZEB2 Transcription regulator 1.44E-03 CDKN2A,EHMT2,PLCG1,SNAI1
MITF Transcription regulator 1.46E-03 CDK2,CDKN2A,CHAF1A,HIF1A,OTX2,SNAI1,
TDG,TP53
GATA1 Transcription regulator 1.54E-03 CDK2,CDK4,CDK6,CDKN2A,COPS5,DICER1,
MYCN,TAL1
SMARCA4 Transcription regulator 1.56E-03 ABCA1,CDK2,CDKN2A,COMMD3-BMI1,
FOXA2,GCLC,LDB1,MYL1,PTCH1,RAD50,
SHH,SS18,TP53,TXNRD1
DLX5 Transcription regulator 1.62E-03 GSC,HAND1,SHH
FGF9 Growth factor 1.62E-03 GCLC,PTCH1,SHH
FOXO4 Transcription regulator 1.64E-03 ACACA,CASP8,CDH5,HIF1A,RBL2
FOXC2 Transcription regulator 1.65E-03 MESP1,NOTCH1,SNAI1,TP53
RAX Transcription regulator 1.66E-03 NOTCH1,OTX2
E4F1 Transcription regulator 1.66E-03 DLD,SLC25A19
DMTF1 Transcription regulator 1.66E-03 CDKN2A,TP53
HDAC5 Transcription regulator 1.76E-03 ARC,CASP8,MAPK7,SLC8A1
AMH Growth factor 1.81E-03 ACVR1,CDKN2A,RBL2
VDR Transcription regulator 1.81E-03 ACACA,HIRA,PLCG1,RAD50,SLC34A2,THBD
FOXA2 Transcription regulator 1.92E-03 CDX2,FOXA2,GATA4,HNF1B,ISL1,SHH,SNAI1
RBPJ Transcription regulator 2.08E-03 CDKN2A,EZH2,FGF4,GNA12,SOX4,TDGF1
GSC Transcription regulator 2.20E-03 SHH,ZEB2
TSG101 Transcription regulator 2.20E-03 TP53,TSG101
PAX3 Transcription regulator 2.21E-03 ARC,ATF2,F2RL1,G6PD,RARRES2,SOX4,TP53
NOTCH1 Transcription regulator 2.31E-03 CDK2,DLD,FLT1,MYCN,NOTCH1,RB1,SNAI1,
TP53
E2F6 Transcription regulator 2.40E-03 CDC7,DDX11,RAD51,RBBP8
GFI1 Transcription regulator 2.46E-03 ATF2,CASP8,ISL1,RAF1,RB1
BMP2 Growth factor 2.69E-03 BMPR2,CDK4,DLX3,IHH,NOTCH1,SMAD4,
SPINT1
FOXA1 Transcription regulator 2.81E-03 CDKN2A,CDX2,FOXA2,HNF1B,ISL1,SHH
TWIST1 Transcription regulator 3.00E-03 CDKN2A,EZH2,SHH,SNAI1,TP53,ZEB2
KLF2 Transcription regulator 3.00E-03 APLNR,FLT1,GATA4,HIF1A,TBX5,THBD
SOX9 Transcription regulator 3.02E-03 CDK4,CDX2,COMMD3-BMI1,IHH
JUN Transcription regulator 3.12E-03 CDKN2A,DICER1,DNMT1,FOXA2,GCLC,
RASA1,SHH,SLC8A1,TP53,TXN,ZEB2
EOMES Transcription regulator 3.14E-03 APLNR,EOMES,FOXA2,GSC,MESP1
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ATF4 Transcription regulator 3.29E-03 ABCA1,CDKN2A,HSP90B1,IHH,MCL1,XRCC1
TGFB3 Growth factor 3.40E-03 CDKN2A,F2RL1,SMAD2,SNAI1,ZEB2
TCF3 Transcription regulator 3.41E-03 AFDN,CDH5,CDK6,CDKN2A,HAND1,HSP90B1,
MYCN,NOTCH1,PLK4
RYBP Transcription regulator 3.49E-03 CDX2,GATA4
MEOX1 Transcription regulator 3.49E-03 CDKN2A,GATA4
BCL6B Transcription regulator 3.49E-03 CASP8,TP53
TBX21 Transcription regulator 3.54E-03 CDK6,EOMES,TP53,ZEB2
SP3 Transcription regulator 3.59E-03 ABCA1,DLX3,FLT1,MYCN,PCYT1A,TP53,
TXNRD1
YBX1 Transcription regulator 3.73E-03 CDK6,CDKN2A,SNAI1,TP53
ETS2 Transcription regulator 3.73E-03 CDKN2A,CDX2,FLT1,RAF1
ING1 Transcription regulator 3.85E-03 CDKN2A,SHH,TP53
ZNF217 Transcription regulator 4.13E-03 EOMES,GATA4,MYCN,TDGF1
TWIST2 Transcription regulator 4.17E-03 MYCN,SNAI1,ZEB2
MAFF Transcription regulator 4.24E-03 GCLC,TXNRD1
FOXD1 Transcription regulator 4.24E-03 ISL1,SHH
RUVBL2 Transcription regulator 4.24E-03 ATF2,TP53
CDKN2C Transcription regulator 4.24E-03 CDKN2A,PTCH1
HNF1B Transcription regulator 4.41E-03 ACVR1,FOXA2,IHH,SNAI1,ZEB2
EGR3 Transcription regulator 4.51E-03 NF1,NOTCH1,PTPN11
NGF Growth factor 4.59E-03 CDK2,CDKN2A,HTT,MYCN,RAC1,RBL2,TXN
STAT1 Transcription regulator 4.63E-03 ABCA1,CASP8,CDK2,HIF1A,ISL1,SHH,SLC8A1,
SMAD2,TP53
GATA3 Transcription regulator 4.70E-03 CDX2,DLX3,EOMES,NOTCH1,RAD50,TAL1,
ZEB2
FOSL1 Transcription regulator 4.78E-03 CDKN2A,GCLC,SNAI1,THBD
HSF2 Transcription regulator 4.87E-03 HIF1A,PSMC4,TXN
HIF1A Transcription regulator 4.89E-03 CDKN2A,FLT1,HIF1A,MCL1,NOTCH1,SHH,
SNAI1,TBX5,TP53,TXN
NFE2L2 Transcription regulator 4.97E-03 ATF7,COPS5,CUL1,G6PD,GCLC,HSP90B1,
PSMC3,TP53,TXN,TXNRD1
BMP10 Growth factor 5.06E-03 BMPR2,TBX20
NRG4 Growth factor 5.06E-03 ABCA1,ACACA
FOXD3 Transcription regulator 5.06E-03 EZH2,FOXA2
HSF4 Transcription regulator 5.06E-03 FGF4,HIF1A
TFAP4 Transcription regulator 5.24E-03 CDK2,CDKN2A,SNAI1
CARM1 Transcription regulator 5.24E-03 CDKN2A,CDX2,GCLC
MEN1 Transcription regulator 5.62E-03 CASP8,CDK4,EZH2
CTCF Transcription regulator 5.74E-03 CDKN2A,GATA4,MYCN,TP53
HDAC4 Transcription regulator 5.81E-03 ARC,CDKN2A,HIF1A,SLC8A1,SMAD4
TLE1 Transcription regulator 5.94E-03 CDKN2A,MCL1
SOX7 Transcription regulator 6.03E-03 DLX3,OTX2,SOX4
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EP300 Transcription regulator 6.72E-03 CDK2,CDKN2A,EP300,EPN1,NOTCH1,PARP1,
PCYT1A,RAD51,RB1,TP53
CBX2 Transcription regulator 6.89E-03 CDKN2A,GATA4
VEGFB Growth factor 6.89E-03 CASP8,TP53,TXNRD1
NFKBIA Transcription regulator 7.04E-03 ATF2,CASP8,CDK2,DAG1,EOMES,HIF1A,RAC1,
SHH,SMAD4,TP53
SKIL Transcription regulator 7.34E-03 FOXA2,GSC,TLN1
ARNTL Transcription regulator 7.34E-03 ACACA,IHH,TP53
ATN1 Transcription regulator 7.49E-03 GRK2,KAT2A,MAX,SOX11,SOX4
MYOD1 Transcription regulator 7.75E-03 ACACA,CDK2,CDX2,DAG1,MYL1,RB1
TBX3 Transcription regulator 7.90E-03 CDKN2A,TP53
ACTN4 Transcription regulator 7.90E-03 MYCN,SNAI1
KDM5B Transcription regulator 7.96E-03 COMMD3-BMI1,GATA4,ISL1,SS18,TAL1
SREBF1 Transcription regulator 8.01E-03 ABCA1,ACACA,CDK4,G6PD,MYL1,PCYT1A,
TP53
MYBL2 Transcription regulator 8.31E-03 CDK2,CDKN2A,FGF4
ANGPT2 Growth factor 8.55E-03 GATA4,HIF1A,RDH10,SNAI1,TP53,XRCC1
MTA1 Transcription regulator 8.81E-03 CDKN2A,EHMT2,SNAI1
NDN Transcription regulator 8.98E-03 CDKN2A,RBL2
GFM1 Translation regulator 9.04E-03 ARC
EEF1E1 Translation regulator 9.04E-03 TP53
PSMD9 Transcription regulator 9.04E-03 SMAD2
CITED4 Transcription regulator 9.04E-03 HIF1A
ZBTB48 Transcription regulator 9.04E-03 CDKN2A
GTF2E1 Transcription regulator 9.04E-03 TBP
DAZL Translation regulator 9.04E-03 CDK2
SUPT4H1 Transcription regulator 9.04E-03 HTT
CAND1 Transcription regulator 9.04E-03 CUL1
GTF2F1 Transcription regulator 9.04E-03 TBP
HOXD12 Transcription regulator 9.04E-03 SHH
RPS27L Translation regulator 9.04E-03 TP53
ESX1 Transcription regulator 9.04E-03 KRAS
GPS2 Transcription regulator 9.34E-03 ABCA1,CDK6,SNX1
ERG Transcription regulator 9.39E-03 EZH2,FLT1,MYCN,POU2F1,PTPN11,SOX4
FGF8 Growth factor 9.76E-03 FGF4,LDB1,OTX2,SHH
FOSL2 Transcription regulator 9.88E-03 ABCA1,SOX4,TP53
CTBP2 Transcription regulator 1.01E-02 CDH5,EOMES
DAXX Transcription regulator 1.01E-02 CASP8,SMAD4
HDAC3 Transcription regulator 1.05E-02 BECN1,CDKN2A,G6PD,TBX5
ZEB1 Transcription regulator 1.10E-02 CDKN2A,COMMD3-BMI1,RBL2
NOG Growth factor 1.10E-02 ISL1,PTCH1,SHH
YY2 Transcription regulator 1.13E-02 TDGF1,TP53
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MSTN Growth factor 1.16E-02 CDK2,HIF1A,MTOR
BMP6 Growth factor 1.17E-02 MYCN,SNAI1,TXNRD1,VCL
FMR1 Translation regulator 1.22E-02 ARC,DAG1,MTOR
COPS5 Transcription regulator 1.26E-02 HIF1A,TP53
BRD7 Transcription regulator 1.26E-02 DICER1,RAD51
NRF1 Transcription regulator 1.29E-02 GCLC,SDHD,TP53
BACH2 Transcription regulator 1.29E-02 CDKN2A,MCL1,TP53
ZNF202 Transcription regulator 1.39E-02 ABCA1,CDKN2A
EIF2S1 Translation regulator 1.39E-02 GCLC,MCL1
NONO Transcription regulator 1.39E-02 ACACA,CDKN2A
NAB2 Transcription regulator 1.39E-02 FLT1,HIF1A
CTGF Growth factor 1.53E-02 HIF1A,LIMS1,SOX4,TP53
SCX Transcription regulator 1.53E-02 SNAI1,TBX20
MAF Transcription regulator 1.63E-02 RAD50,TP53,TXN
SALL4 Transcription regulator 1.67E-02 COMMD3-BMI1,FGF4
FOXC1 Transcription regulator 1.67E-02 MESP1,NOTCH1
DKK1 Growth factor 1.71E-02 CDKN2A,TP53,TTYH1
NRIP1 Transcription regulator 1.78E-02 ACACA,CDKN2A,SLC25A19
EIF4B Translation regulator 1.80E-02 MCL1
ALX1 Transcription regulator 1.80E-02 SNAI1
HOXC5 Transcription regulator 1.80E-02 SHH
ADNP Transcription regulator 1.80E-02 TP53
ZBTB49 Transcription regulator 1.80E-02 RB1
VENTX Transcription regulator 1.80E-02 CDKN2A
ZNF326 Transcription regulator 1.80E-02 RAD50
SNCAIP Transcription regulator 1.80E-02 TP53
ZNF197 Transcription regulator 1.80E-02 HIF1A
BCLAF1 Transcription regulator 1.80E-02 TP53
ARNTL2 Transcription regulator 1.80E-02 THBD
PREB Transcription regulator 1.80E-02 ABCA1
ONECUT2 Transcription regulator 1.80E-02 FOXA2
UHRF1 Transcription regulator 1.80E-02 RB1
DDX20 Transcription regulator 1.80E-02 TP53
HTATIP2 Transcription regulator 1.82E-02 SNAI1,TP53
HEY1 Transcription regulator 1.97E-02 GATA4,TP53
SMARCB1 Transcription regulator 2.02E-02 CDC7,CDKN2A,MCM10,PLK4,TP53
LEF1 Transcription regulator 2.03E-02 CDKN2A,PTCH1,TP53
GH1 Growth factor 2.06E-02 ACVR1,NRAS,SNAI1,XRCC1
FOXL2 Transcription regulator 2.11E-02 CDKN2A,RSPO3,SOX4
AIRE Transcription regulator 2.11E-02 BMP10,EOMES,MGAT1
E2F5 Transcription regulator 2.13E-02 BECN1,MYCN
NODAL Growth factor 2.13E-02 CDK2,FGF4
(Continues)
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TABLE 4 (Continued)
Upstream of arrest in embryo growth
Upstream regulator Molecule type P-value of overlap Target molecules in dataset
SOX6 Transcription regulator 2.13E-02 MYL1,TP53
HEXIM1 Transcription regulator 2.13E-02 HIF1A,TP53
NFIC Transcription regulator 2.13E-02 CDKN2A,TP53
LEP Growth factor 2.14E-02 ACACA,ASB4,FLT1,GCLC,ISL1,MCL1,NOTCH1,
RAC1,TP53
HOXA9 Transcription regulator 2.21E-02 CDKN2A,HIRA,RAD51,SHH,SOX4
DTX1 Transcription regulator 2.29E-02 MCL1,SNAI1
SPDEF Transcription regulator 2.37E-02 HIF1A,SMAD2,SMAD4
HOXA10 Transcription regulator 2.46E-02 FLT1,MAX,MYCN,THBD,TP53
SP4 Transcription regulator 2.64E-02 ARC,FLT1
NFIL3 Transcription regulator 2.64E-02 ACACA,EOMES
KLF6 Transcription regulator 2.66E-02 MCL1,PTCH1,SHH
THAP11 Transcription regulator 2.69E-02 GATA4
SOX12 Transcription regulator 2.69E-02 FGF4
TAF3 Transcription regulator 2.69E-02 GATA4
OSR2 Transcription regulator 2.69E-02 OSR1
LHX8 Transcription regulator 2.69E-02 ISL1
GTF2F2 Transcription regulator 2.69E-02 TBP
SERTAD1 Transcription regulator 2.69E-02 CDK4
GTF2H1 Transcription regulator 2.69E-02 TBP
ARID1B Transcription regulator 2.69E-02 ARC
HOXB2 Transcription regulator 2.69E-02 OTX2
RPS14 Translation regulator 2.69E-02 TP53
L3MBTL2 Transcription regulator 2.69E-02 CDC7
SOX21 Transcription regulator 2.69E-02 CDX2
ATF7IP Transcription regulator 2.69E-02 CDKN2A
VEZF1 Transcription regulator 2.69E-02 UBTF
CASP8AP2 Transcription regulator 2.69E-02 MCL1
MXD3 Transcription regulator 2.69E-02 MYCN
FOS Transcription regulator 2.75E-02 DNMT1,GATA4,HSP90B1,Macf1,Nrg1,SNAI1,
SUMO2,TAL1,TP53,TXN
MYB Transcription regulator 2.98E-02 NOTCH1,NRAS,SHH,SNAI1
TCF7L1 Transcription regulator 3.00E-02 EOMES,FOXA2
SOX10 Transcription regulator 3.00E-02 DAG1,NOTCH1
MLXIPL Transcription regulator 3.00E-02 ACACA,HIF1A
NEUROG3 Transcription regulator 3.06E-02 ACACA,ISL1,XRCC1
TFAP2C Transcription regulator 3.06E-02 CDX2,EOMES,RASA1
IFI16 Transcription regulator 3.16E-02 CDKN2A,GATA4,XRCC1
TBX2 Transcription regulator 3.16E-02 CDKN2A,DNMT1,EZH2
CREB1 Transcription regulator 3.39E-02 ABCA1,ACVR2A,ARC,FLT1,MCL1,NF1,
NOTCH1,PNO1,RB1,TXN
FGF16 Growth factor 3.57E-02 SNAI1
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TABLE 4 (Continued)
Upstream of arrest in embryo growth
Upstream regulator Molecule type P-value of overlap Target molecules in dataset
PDLIM1 Transcription regulator 3.57E-02 SNAI1
JDP2 Transcription regulator 3.57E-02 TP53
HEY2 Transcription regulator 3.57E-02 GATA4,TBX5
HLX Transcription regulator 3.57E-02 CDKN2A,RB1
SUFU Transcription regulator 3.57E-02 PTCH1
EAF2 Transcription regulator 3.57E-02 HIF1A
HOXC13 Transcription regulator 3.57E-02 CDKN2A
AES Transcription regulator 3.57E-02 FOXA2
FOXH1 Transcription regulator 3.57E-02 FOXA2
TBPL1 Transcription regulator 3.57E-02 NF1
RAD21 Transcription regulator 3.57E-02 BMPR2,SOX4
NFYB Transcription regulator 3.59E-02 AMD1,CDKN2A,GNA12,RAD51,SNAI1,UHRF1
MRTFA Transcription regulator 3.60E-02 CDKN2A,RAC1,TAL1,VCL
CDX2 Transcription regulator 3.68E-02 CDX2,HNF1B,MYCN,SNAI1
USF1 Transcription regulator 3.72E-02 ABCA1,CDK4,TP53
IRF8 Transcription regulator 3.76E-02 ACVRL1,ATF7,NF1,TP53
SOX17 Transcription regulator 3.78E-02 FOXA2,GATA4
ETV4 Transcription regulator 3.78E-02 CDKN2A,SHH
EPAS1 Transcription regulator 3.82E-02 ACACA,FLT1,FXN,HIF1A,NOTCH1
TBX5 Transcription regulator 3.83E-02 CDK2,GATA4,SLC8A1
PIAS1 Transcription regulator 3.98E-02 ACACA,MCL1
NFYA Transcription regulator 4.07E-02 COMMD3-BMI1,NOTCH1,POU2F1
YY1 Transcription regulator 4.17E-02 CDKN2A,DLX3,MYL1,RAD51,TP53,UHRF1
GTF2B Transcription regulator 4.19E-02 RBBP8,TBP
XBP1 Transcription regulator 4.24E-02 ACACA,BECN1,HSP90B1,PCYT1A,TXN
ONECUT1 Transcription regulator 4.35E-02 ACVR1,CDK2,FOXA2,HNF1B,KAT7,TSG101
MTDH Transcription regulator 4.40E-02 CASP8,HIF1A
PGF Growth factor 4.40E-02 FLT1,HIF1A
NFE2L1 Transcription regulator 4.40E-02 GCLC,PSMC3
PRRX2 Transcription regulator 4.44E-02 SHH
TRIM29 Transcription regulator 4.44E-02 SNAI1
SSBP2 Transcription regulator 4.44E-02 LDB1
MTF2 Transcription regulator 4.44E-02 CDKN2A
RREB1 Transcription regulator 4.44E-02 CDKN2A
PHF6 Transcription regulator 4.44E-02 UBTF
TAF9 Transcription regulator 4.44E-02 TP53
ELAVL4 Translation regulator 4.44E-02 MYCN
BRCA2 Transcription regulator 4.44E-02 TP53
BRF1 Transcription regulator 4.44E-02 TBP
GTF2H4 Transcription regulator 4.44E-02 CDK4
MYCL Transcription regulator 4.44E-02 CDK4
(Continues)
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desired developmental Hamburger Hamilton (HH) stages
were reached.10 Optimal conditions for high transfection
efficiency applying one-sided electroporation in ovo
were determined to 5 pulses of 30 ms each at 22 V.
Ringer's balanced salt solution (solution-1:144 g NaCl,
4.5 g CaCl•2H2O, 7.4 g KCl, ddH2O to 500 mL; solution-
2:4.35 g Na2HPO4•7H2O, 0.4 g KH2PO4, ddH2O to
500 mL [adjust final pH to 7.4]) containing 1% penicillin/
streptomycin was used in all experiments. Morpholinos
used were from GeneTools with the following sequences;
splice targeting EPAS1 oligo (50-GAAAGTGTGAGGGAA
CAAGTTACCT-30) and a corresponding 50-mispair oligo
(50-GAtAcTGTcAGGcAACAAcTTACCT-30). Morpholinos
were injected at a concentration of 1 mM and co-
electroporated with a GFP tagged empty control vector
(1 μg/μL). RFP-tagged EPAS1 overexpression construct or
corresponding empty control vector were electroporated
at a concentration of 2.5 μg/μL. CRISPR constructs with
gRNA nontargeting control (#99140, Addgene) or gRNAs
targeting EPAS1 (EPAS1.1.gRNA Top oligo—50 ggatg
GCTCAGAACTGCTCctacc 30, Bot oligo—50 aaacggtag
GAGCAGTTCTGAGCc 30; EPAS1.2.gRNA Top oligo—50
ggatgAAGGCATCCATAATGCGCC 30, Bot oligo—50
aaacGGCGCATTATGGATGCCTTc; 30; EPAS1.3.gRNA
Top oligo—50 ggatgAAATACATGGGTCTCACCC 30, Bot
oligo—50 aaacGGGTGAGACCCATGTATTTc 30) were
cloned into U6.3 > gRNA.f + e (#99139, Addgene) and
electroporated at a concentration of 1.5 μg/μL, and
accompanying Cas9-GFP (#99138, Addgene) at 2 μg/μL.40
All constructs were injected at HH stage 10+/11 into the
lumen of the neural tube from the posterior end and
embryos were electroporated in ovo applying electrodes
4 mm apart, covering the whole embryo. One-sided electro-
poration was performed to allow for an internal control
side within each individual embryo. Embryos were allowed
to sit at room temperature for 6 to 10 hours before further
incubation of the embryos at 37.5C in order to allow the
Cas9 protein to fold. Importantly, apart for analysis on
embryo growth (ie, age determination), all analyses were
performed on sections/cells at the trunk axial level of the
embryo.
For harvesting of tissue for RNA extraction, embryos
were incubated at 37.5C for 24 (morpholinos and over-
expression vectors) or 36 (CRISPR/Cas9) hours post-
electroporation. The trunk portion of neural tubes was
dissected and immediately snap frozen before RNA extrac-
tion and qPCR analysis.
4.5 | Cloning
To overexpress HIF-2α, the Gallus gallus EPAS1 coding




G-30 and cloned into the pCI H2B-RFP vector (Addgene
plasmid #92398). For CRISPR/Cas9 targeting, oligos
designed to target EPAS1 at three different locations
(EPAS1.1, EPAS1.2, and EPAS1.3) were annealed pairwise
at a concentration of 100 μM per oligo using T4 DNA
Ligase Buffer in dH2O by heating to 95C for 5 minutes.
The annealed oligo reactions were cooled to room temper-
ature and diluted. The U6.3 > gRNA.f + e (#99139,
Addgene) vector was digested over night with BsaI-HF
enzyme (New England Biolabs) and gel extracted. gRNAs
were cloned into the digested U6.3 > gRNA.f + e vector
using T4 DNA Ligase (New England Biolabs) at room
temperature for 20 minutes. Successful inserts were iden-
tified by colony PCR using U6 sequencing primer and
gRNA reverse oligo specific to each EPAS1 gRNA.
4.6 | Neural tube dissections for
crestosphere cultures
Neural tubes from respective axial levels were carefully
dissected out from embryos at designated somite stages.
TABLE 4 (Continued)
Upstream of arrest in embryo growth
Upstream regulator Molecule type P-value of overlap Target molecules in dataset
Foxp2 Transcription regulator 4.44E-02 MYCN
Meis1 Transcription regulator 4.44E-02 HIF1A
MAX Transcription regulator 4.57E-02 CDK4,EZH2,RBBP8
POU4F2 Transcription regulator 4.62E-02 OTX2,SHH
MYOCD Transcription regulator 4.70E-02 GATA4,HAND1,TP53
ATF2 Transcription regulator 4.96E-02 CDKN2A,MCL1,NOTCH1
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For cranial-derived cultures, the very anterior tip was
excluded, and the neural tube was dissected until the first
somite level as previously described.26 For trunk-derived
cultures, the neural tube was dissected between somite
10 to 15 as previously described.24,25 Pools of neural tubes
from four to six embryos were used for each culture.
FIGURE 14 Gene set enrichment analysis identifies key molecules for migration of tumor cells. Deeper analysis of overlap of genes
involved in downstream process “migration of tumor cells” (Figure 11A,B) and genes from RNA sequencing data. The shape of molecules
and their meaning, that is, correspondence to protein family and so forth, is found here: http://qiagen.force.com/KnowledgeBase/
KnowledgeIPAPage?id=kA41i000000L5rTCAS. As an example, the diamond-shaped molecules correspond to enzymes, oval standing shapes
should be read as transmembrane receptors and lying oval shapes are transcription regulators. Green nodes indicate downregulated
molecules. The intensity of the color reveals the strength of the expression, that is, the stronger the color the more significant. The dashed
lines indicate an indirect interaction between molecules in the network whereas solid lines are direct interactions. The solid arrow explains
the direction of the indicated interaction. A line, solid, or dashed, without an arrowhead indicate an RNA-RNA interaction
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4.7 | Crestosphere cell culture
Neural tube derived cells were cultured in NC medium
(DMEM with 4.5 g/L glucose (Corning), 7.5% chick embryo
extract (MP Biomedicals, Santa Ana,California), 1X B27
(Life Technologies), basic fibroblast growth factor (bFGF,
20 ng/mL) (Peprotech, Stockholm, Sweden), insulin
growth factor-I (IGF-I, 20 ng/mL) (Sigma Aldrich, Darm-
stadt, Germany), retinoic acid (RA; 60 nM for cranial and
180 nM for trunk, respectively) (Sigma Aldrich), and
25 ng/mL BMP-4 (for trunk) (Peprotech)) in low-adherence
T25 tissue culture flasks as described previously.24,25
4.8 | Self-renewal assay
Chick embryos at developmental HH stage 10+/11 were
injected and electroporated with CRISPR/Cas9 constructs
and allowed to develop at 37.5C to reach HH stage
13+/14−. Crestosphere cultures were established from
embryos electroporated with control, EPAS1.1 or EPAS1.2
constructs. Crestospheres were dissociated into single cells
using Accutase (Sigma Aldrich; incubation at 37C for
40 minutes with 1 minute of pipetting every 10 minutes),
and individual cells were manually picked using a p10
pipette tip under a microscope. Single cells were trans-
ferred to 96-well plates prepared with 100 μL of NC
medium supplemented with RA and BMP-4.25 The abso-
lute number of spheres formed in each well was quantified
manually under the microscope. Sphere diameter was
manually measured using the ImageJ software (spheres
measured n = 33 and n = 27 for CTRL and EPAS1.2,
respectively).
4.9 | EdU pulse chase labeling
Proliferation was measured using the Click-iT EdU
Cell Proliferation kit (Invitrogen #C10337) according to
the manufacturer's recommendations with optimizations
from Warren et al.23 Chick embryos at developmental
HH stage 10+/11 were injected and electroporated with
morpholino or overexpression constructs and allowed to
develop for an additional 24 hours at 37.5C. Eggs were
then reopened and EdU solution (500 μM in PBS-DEPC)
was added. Eggs were resealed and incubated at 37.5C
for another 4 hours before dissection in Ringer's solution
and fixed in 4% paraformaldehyde overnight. Embryos
were washed in PBS-DEPC, H2O, and 3% BSA in PBS-
DEPC before permeabilization in 0.5% Triton-X. Embryos
were hybridized in reaction cocktail (Click-iT Reaction
buffer, CuSO4, Alexa Fluor 488 Azide and reaction buffer
additive), washed and DAPI stained. Embryos were after
another round of washing processed through a sucrose
gradient and embedded in gelatin.
4.10 | Whole mount in situ hybridization
For whole mount in situ hybridization, embryos were fixed
in 4% PFA and washed in DEPC-PBT. Samples were gradu-
ally dehydrated by bringing them to 100% MeOH and kept
at −20C until use. In situ hybridization was performed as
previously described.41 Embryos were rehydrated back to
100% PBT, treated with Proteinase K/PBT, washed in
2 mg/mL glycine/PBT and postfixed in 4% paraformalde-
hyde/0.2% glutaraldehyde for 20 minutes. Embryos were
then prehybridized in hybridization buffer for 2 hours at
70C and hybridized with Digoxigenin (DIG)-labeled
TFAP2B probe overnight at 70C. Embryos were washed
in wash solutions I and II (50% formamide, 1% sodium
dodecyl sulfate [SDS] and 5X SSC [NaCl and Na citrate] or
2X SSC, respectively), and blocked in 10% sheep serum for
2 hours followed by incubation with an anti-DIG antibody
(1:2000) (Roche) in TBST/1% sheep serum overnight at
FIGURE 15 Schematic of the gene regulatory network
including EPAS1 and downstream CDX2 and HNF1B coupled to
arrested embryo growth
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TABLE 5 Full list of genes identified as potential upstream regulators of HIF-2α from RNA sequencing data. Target molecules are








































































































































FGF1 Growth factor 1.36E-02 ALB,CDH1,POSTN

















WISP2 Growth factor 1.82E-02 CDH1,CLDN1
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4C. On day 3, embryos were washed in TBST throughout
the day and overnight. Embryos were washed in alkaline
phosphatase buffer (NTMT; 100 mM NaCl, 100 mM Tris-
Cl [pH 9.5], 50 mMMgCl2, 1%Tween-20) before visualizing
the signal using NBT/BCIP (Sigma Aldrich). Stained
embryos were rinsed in PBT for 20 minutes and postfixed
in 4% PFA/ 0.1% glutaraldehyde overnight when consid-
ered complete. Embryos were then dehydrated in MeOH to
be stored at −20C. Embryos were later embedded in
blocks of gelatin for transverse sectioning at 8 μm using a
cryostat. Hybridization probe for avian TFAP2B was a kind
gift from Dr Felipe Vieceli.
4.11 | RNA sequencing
Chick embryos of stage HH10+/11 were from the posterior
end injected with EPAS1 targeting or corresponding 50-
mispair morpholinos into the lumen of neural tubes and
subsequently electroporated for construct uptake. Follow-
ing 24 hours of incubation at 37.5C, embryos were
removed from the eggs in Ringer's solution. The neural
tube portion at the trunk axial level of individual embryos
were carefully dissected, removing surrounding mesoder-
mal tissue, and transferred to Eppendorf tubes (neural tube
tissue from one embryo per Eppendorf) that were snap fro-
zen. RNA was extracted from each individual neural
tube (five samples per condition [EPAS1 and 50-mispair,
respectively]) using the RNAqueous Micro Kit (Ambion,
#AM1931). Sequencing was performed using NextSeq
500 (Illumina). Alignment of reads was performed using
the HISAT2 software and the reference genome was from
the Ensemble database (Gallus gallus 5.0). Expression
counts were performed using the StringTie software and
DEG analysis was performed using DESeq2. To obtain a
relevant working list out of the 1105 significantly DEGs,
we set a cut-off at P < .005 and removed all hits that were
NA, ending up with 97 genes. Significance (P values) was
DESeq2 derived.42 RNA sequencing data have been depos-
ited in NCBI's Gene Expression Omnibus43 and are accessi-
ble through GEO Series accession number GSE140319.
4.12 | Bioinformatics
GSEA for gene ontology, network and functional analyses
were generated through the use of Panther database (ana-
lyses performed autumn 2018; (http://pantherdb.org/)44
together with the Ingenuity Pathway Analysis (IPA) soft-
ware45 (QIAGEN Inc., https://www.qiagenbioinformatics.
com/products/ingenuity-pathway-analysis). For a hypothesis-
free/exploratory analysis of the 97 DEGs, IPA was used
(P-value calculations using right-tailed Fisher Exact Test).
IPA was mainly used for deeper exploration of the data
where the biological hypotheses generated for the project
were further explored. Here, a hypotheses-driven approach
was taken where the following categories found from the
IPA analysis of the 97 DEGs were further investigated;
“Cellular Movement,” within the “Molecular and Cellular
Function” result category, “Embryonic Development,”
within the category “Physiological System Development
and Function,” and “Tumor Morphology,” within the
“Disease and Disorders” category. These three biological
networks were further investigated within the data set at
hand. The investigation for the possible overlap and con-
nections between these networks in the context of the data
were hence explored.
4.13 | Cryosections
Fixed embryos were incubated in a sucrose gradient (5%
sucrose for 10 minutes and 15% sucrose for 10 minutes
up to several hours) followed by incubation in 7.5% gela-
tin over night at 37C. Gelatin embedded samples were
cryosectioned at 7 to 20 μm.
4.14 | Immunohistochemistry and
immunofluorescence
Immunohistochemistry on mouse fetal tissue for HIF-2α
(NB100-132, Novus Biologicals) and TH (ab112, Abcam)

















Abbreviation: DEGs, differentially expressed genes; HIF, hypoxia inducible factor.
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counterstained with hematoxylin. Detection of HIF-2α by
immunofluorescence was performed on sections from the
trunk axial level of embryos (avian and human) that had
been harvested, fixed as whole embryos in 4% PFA over-
night, incubated in 5% sucrose for 10 minutes, 15% sucrose
for 4 hours and gelatin overnight. Embryos were then
embedded in gelatin and snap frozen. Dry embryo sections
were incubated in ice-cold acetone followed by 0.3%
Triton-X in PBS. After washing in PBS, slides were blocked
in DAKO serum-free ready-to-use block (DAKO, #X0909)
for 1 hour before incubation with primary antibodies
(in DAKO antibody diluent with background reducing
components [DAKO, #S3022]) overnight (HIF-2α, ab199,
Abcam; HNK-1, 3H5, DSHB). Slides were washed in PBS
and incubated with rabbit linker (DAKO, #K8019) followed
by secondary antibody in 1% BSA/PBS. Detection of HNK1
and SOX9 by immunofluorescence was performed by block-
ing (10% goat serum and 0.3% Triton-X in TBST) of embryo
sections followed by incubation with primary antibodies
(SOX9, ab5535, Millipore) over night at +4C. Slides
were washed and incubated with secondary antibodies and
DAPI for nuclear staining for 1 hour at RT before washing
and mounting. Fluorescent images were acquired using
an Olympus BX63 microscope, DP80 camera, and cellSens
Dimension v 1.12 software (Olympus Cooperation).
Detailed information on antibodies can be found in Table 6.
4.15 | Western blot
Extracted proteins were separated by SDS-PAGE, trans-
ferred to HyBond-C-Extra nitrocellulose membranes,
blocked, and incubated with primary antibodies (HIF-2α,
ab199, Abcam; SDHA, ab14715, Abcam) at 4C overnight.
The next day, membranes were incubated with HRP-
conjugated antibodies and proteins detected by ECL solu-
tion. Detailed information on antibodies can be found in
Table 6.
TABLE 6 Detailed information of antibodies used in this study
Species Dilution Source Product #
IF antibodies
Primary antibody
HNK1 Mouse 1:5 Hybridoma bank 3H5
HIF-2α Rabbit 1:50 Abcam ab199
SOX9 Rabbit 1:1000 Millipore ab5535
Secondary antibody
Anti-mouse Alexa Fluor-594 Goat 1:1000 Invitrogen A-11032
Anti-rabbit Alexa Fluor-546 Donkey 1:1000/1:500 Invitrogen A-10040
Anti-mouse Alexa Fluor-488 Goat 1:1000 Invitrogen A-11008
IHC antibodies
Primary antibody
HIF-2α Mouse 1:1000 Novus Biologicals NB100-132
HIF-2α Rabbit 1:4000 Abcam ab199
TH Rabbit 1:1600 Abcam ab112
In situ antibodies
Anti-dig-AP Mouse 1:2000 Roche Diagnostics 11 093 274 910
Nuclear staining
DAPI 1:3000 Dako D3571
Western blot antibodies
Primary antibody
HIF-2α Rabbit 1:200 Abcam ab199
SDHA Mouse 1:4000 Abcam ab14715
Secondary antibody
Anti-rabbit Monkey 1:3000 Invitrogen 65-6120
Anti-mouse Sheep 1:5000 Invitrogen 62-6520
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4.16 | RNA extraction and quantitative
real-time PCR
Total RNA was extracted using the RNAqueous Micro
Kit (Ambion, #AM1931). cDNA synthesis using random
primers and qRT-PCR was performed as previously
described.27 Relative mRNA levels were normalized to
expression of two reference genes (18S, 28S) using the
comparative Ct method.46 Detailed information of primer
sequences can be found in Table 7.
4.17 | RNAi experiments
SK-N-BE(2)c cells were transfected with ON-TARGETplus
Nontargeting Control siRNA #2 (D-001810-02-05), ON-
TARGETplus siRNA Targeting humanHIF1Α (J-004018-07)
or ON-TARGETplus siRNA Targeting human EPAS1
(J-004814-06), all from Dharmacon, using Lipofectamine
2000 or RNAiMAX. Cells were then placed in 21% or 1% oxy-
gen for 48 hours before harvest. SK-N-BE(2)c cells were
treated with 200 μM 2,20-dipyridyl (DIP), an iron chelator
that promotes stabilization of HIF-α at normoxic conditions
for 4 hours before harvest and were used as positive control
for western blot detection of HIF-2α.
4.18 | Oxygen sensing
Oxygen concentrations were measured through the trunk
region of developing chick embryos ex ovo within
30 minutes from dissection using microsensors in a flow
system of MQ water. We performed trials to confirm that
oxygen concentrations are largely stable within the tissue
ex ovo over at least 5 hours. Microprofiles were measured
in 50 embryos in developmental stages HH10 to HH24.
Embryos were removed from the egg using filter paper
as described in Mohlin and Kerosuo,24 submerged in a
plate with constant flow of newly shaken MQ of room
temperature, and immediately measured. Oxygen micro-
sensors were constructed and calibrated as described by
Revsbech and Andersen,47 mounted on a micromanipula-
tor. The microsensor was manually probing the trunk
region and data logged every second. Within the micro-
profile, 10 consecutive data points of the lowest oxygen
concentrations were averaged and set as representing the
trunk neural tube. A two-point calibration was performed
using the newly shaken MQ (100% oxygen saturation)
and by adding sodium dithionite to nonflowing MQ in
the plate after measurements (0% oxygen saturation).
Salinity of the tissue was determined using a conductivity
meter (WTW 3110) and room temperature noted. The
tissue is considered a liquid, where full oxygen saturation
at 5‰ salinity and 25C corresponds to 250 μm/L,
160 mmHg, or 21% atmospheric O2. Data were averaged
for each HH stage including one measurement of the pre-
vious and subsequent HH stages. Replicates vary from
3 to 10 biologically independent data points. Data are
presented as percent of maximum saturation in the solu-
tion of the specific temperature and salinity.
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4.19 | Quantifications
Embryonic development was quantified in two ways; by
determining the HH stage of embryos in ovo using head and
tail morphology or by counting the number of somites of dis-
sected embryos ex ovo. The number of embryos (n) for each
group is denoted in respective figure legend. The fraction of
proliferating EdU+ cells was determined by quantifying the
number of GFP+ proliferating cells as well as RFP+ con-
struct targeted cells and dividing the number of double posi-
tive cells with the number of RFP+ only cells. Premigratory
and recently delaminated trunk neural crest cells were
included (distinguished by the dotted line in figures). Quan-
tification of migration was performed by calculating the area
of detected HNK1 using the ImageJ software. The area of
HNK1+ on the electroporated side of the embryos was nor-
malized to that of the control side of the same embryo.
4.20 | Statistical methods and data sets
One-way analysis of variance or two-sided student's
unpaired t test was used for statistical analyses. For down-
stream analysis on the 97 DEGs where the software IPA
was used, the statistical tests considered were P-value cal-
culations using right-tailed Fisher exact test.
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